Wells Ex Rel. Maihafer v. Ortho Pharmaceutical Corp.

615 F. Supp. 262, 1985 U.S. Dist. LEXIS 17397

• Court: District Court, N.D. Georgia
• Decided: July 29, 1985
• Docket: Civ. A. C82-1921A
• Status: Published

Opinion

ORDER

SHOOB, District Judge.

Plaintiffs—Mary Maihafer and Gary S. Wells, on behalf of their infant daughter Katie Laurel Wells, and Mary Maihafer, individually—brought this products liability action against defendant Ortho Pharmaceutical Corporation to recover damages arising from multiple birth defects suffered by Katie Wells. The central issues that emerged at trial were (1) whether Ortho-Gynol Contraceptive Jelly, a spermicide manufactured and marketed by defendant and allegedly used by plaintiff Mary Maihafer several months before and several weeks after Katie Wells was conceived, proximately caused these birth defects; and (2) whether defendant negligently failed to warn plaintiff Mary Maihafer that an increased risk of birth defects accompanied the use of its product.

At the parties’ request, the case was tried before the Court without a jury. 1 After an exhaustive two-week trial with competent and well-prepared counsel for each side, the Court’s decision was not an easy one. The medical and scientific evidence presented was in direct conflict. Still, the Court recognized then, and reiterates now, that its task was not to presume the expertise to resolve, once and for all, the dispute within the scientific community about the safety of spermicides. Rather, the Court’s function was to render a legal decision, not a medical one. That is, the Court’s duty was to weigh carefully the evidence that these parties presented to this Court in the trial of this case and to determine with reference to the facts of the case at hand whether plaintiffs had satisfied their burden of proving that they were entitled to the relief sought.

At trial the key evidence was the testimony of highly qualified expert witnesses and various medical and scientific studies. In considering this evidence, the Court kept in mind plaintiffs’ burden of proof: plaintiffs could not recover if the Court found that there was only a “bare possibility” that the spermicide caused these birth defects or that other theories of causation were equally plausible. See Maddox v. Houston County Hospital Authority, 158 Ga.App. 283, 284, 279 S.E.2d 732 (1981). Rather, to authorize recovery plaintiffs’ evidence must have shown to a “reasonable degree of medical certainty” that defendant’s product was responsible. Parrott v. Chatham County Hospital Authority, 145 Ga.App. 113, 115, 243 S.E.2d 269 (1978); see also Defendant’s Trial Brief at 3.

The testimony of plaintiffs’ and defendant’s experts conflicted on several crucial points. Experts on each side testified that, to a reasonable degree of medical certainty, their side’s theory of the case was correct. Attempting to resolve these direct conflicts in the experts’ opinions, throughout the trial the Court regularly examined daily transcripts of much of the expert testimony and spent an entire weekend reviewing the studies introduced. Although some of the studies suggested a connection between spermicides and birth defects, overall the studies failed to show conclusively whether or not the spermicide caused any or all of the birth defects suffered by Katie Wells. The Court emphasizes, however, that plaintiffs’ ultimate burden was not to produce an unassailable scientific study which proves that spermicides have caused birth defects in rats, rabbits, or members of a large group health plan, but rather to show from all the evidence presented, to a reasonable degree of medical certainty, that the spermicide caused some or all of Katie Wells’ birth defects.

The Court’s decision, therefore, turned on the oral testimony of a variety of expert witnesses whose opinions often were diametrically opposed on the major issues presented in the case. In assessing the credibility of these witnesses, the Court considered each expert’s background, training, experience, and familiarity with the circumstances of this particular case; and the Court evaluated the rationality and internal consistency of each expert’s testimony in light of all the evidence presented. The Court paid close attention to each expert’s demeanor and tone. Perhaps most important, the Court did its best to ascertain the motives, biases, and interests that might have influenced each expert’s opinion.

With few exceptions, the Court found the testimony of plaintiffs’ experts generally to be competent, credible, and directed to the specific circumstances of this case. The testimony of defendant’s experts, in contrast, often indicated bias or inconsistency. Primarily because the Court found plaintiffs’ expert testimony to be far more credible than defendant’s, at the conclusion of trial the Court announced that plaintiffs had carried their burden of proving that the spermicide proximately caused some, but not all, of Katie Wells’ birth defects and that defendant had been negligent in failing to warn plaintiff Mary Maihafer of this danger. As a result, the Court awarded damages to plaintiffs Katie Wells and Mary Maihafer. The following discussion explains in detail how the Court arrived at this decision from the evidence presented at trial and sets forth the Court’s findings of fact and conclusions of law in accordance with Rule 52, Fed.R.Civ.P.

Plaintiffs’ Contentions

Plaintiff Mary Maihafer, the mother of plaintiff Katie Wells, is a thirty-two year old college instructor who, plaintiffs contended, has no family history of birth defects and who in 1979 gave birth to a child with no birth defects. According to plaintiffs, Gary S. Wells, the father of Katie Wells, also has no family history of birth defects and is the father of a child born in 1974 without birth defects.

In July 1980, Ms. Maihafer obtained from her gynecologist a prescription for a diaphragm to be used for contraception and a sample tube of Ortho-Gynol Contraceptive Jelly (“the Product”). At that time, plaintiffs contended, a nurse instructed her on the proper use of the diaphragm and spermicidal jelly, and Ms. Maihafer read the “Directions for Using Ortho-Gynol Contraceptive Jelly,” which accompanied the Product. 2

Plaintiffs alleged that Ms. Maihafer had used the diaphragm and Ortho-Gynol Contraceptive Jelly in accordance with these instructions every time she had sex with Gary Wells from the time the diaphragm was prescribed in late July 1980 until mid-November 1980. Transcript at 80-81. Notwithstanding these precautions, Ms. Maihafer missed her menstrual period that was due to occur around November 1,1980, and later discovered that she had become pregnant in October 1980.

On July 1, 1981, Ms. Maihafer gave birth to plaintiff Katie Wells, who was born with the following birth defects: (1) a cleft lip; (2) an abnormal formation and shortening of her right hand; (3) the absence of the distal joint of her right ring finger; (4) the complete lack of a left arm; and (5) only partial development of the left clavicle and shoulder. Later Katie Wells was diagnosed as also suffering from hypoplasia of the right optic nerve, which according to plaintiffs has made her almost ninety percent blind in that eye. Transcript at 11.

Plaintiffs filed this action on September 2. 1982, seeking to recover for damages to both Katie Wells and Mary Maihafer. 3 The complaint stated causes of action for negligence, strict products liability, intentional tort, and breach of warranty. 4 Plaintiffs asserted that the spermicide’s active ingredient, a non-ionic surfactant that works to break down sperm cell membranes, caused these birth defects through one of the following “mechanisms”:

(1) injury to a sperm that ultimately fertilizes an egg;

(2) injury to an unfertilized egg;

(3) injury to a fertilized egg or zygote; or

(4) injury to the developing fetus, either by direct contact with the fetus or by absorption by the mother.

Transcript at 21-22. Moreover, plaintiffs alleged that, at the time Mary Maihafer purchased and used the Product, defendant knew or should have known of certain studies that were available to the scientific community linking the use of spermicides to birth defects in the children of mothers who used spermicides around the time of conception.

According to plaintiffs, defendant’s actual or constructive knowledge of this increased risk imposed on defendant a duty to warn health professionals and prospective users of this risk by placing a warning on the Product. Plaintiffs argued that defendant’s failure to warn constituted a defect in the Product and thus established defendant’s liability under a strict products liability theory. Further, plaintiffs maintained that the failure to warn was also a basis for finding defendant negligent. Transcript at 13. Finally, plaintiffs maintained that they were entitled to punitive damages because defendant's failure to warn was part of a conscious decision to protect its market share. Transcript at 34-35.

Defendant’s Contentions

Defendant vehemently denied any association between the use of Ortho-Gynol Contraceptive Jelly and birth defects. Defendant pointed out that the Product’s active ingredient, a non-ionic surfactant called pdiisobutylphenoxypolyethoxyethanol or oetoxynol-9, is almost identical to non-ionic surfactants used by other manufacturers of spermicides. 5 Since 1950, defendant has sold the Product in its present form to millions of women.

Defendant maintained that the Product is safe and effective when properly used. Defendant suggested that Ms. Maihafer may not have used the spermicide in strict accordance with the instructions. Defendant also pointed out that the Product carried a warning that no form of birth control is one hundred percent effective. Transcript at 36-37.

According to defendant, no additional warning was or is necessary. Defendant argued that at the time of Katie Wells’ conception in the fall of 1980, no published reports or studies had concluded that spermicides cause birth defects; further, according to defendant, it had received no other complaints nor had access to any other evidence suggesting a link between its Product and birth defects.

Defendant argued that, on the contrary, “[t]he overwhelming weight of the credible scientific evidence has established that use of such products does not cause birth defects.” Consolidated Pretrial Order at 9. Defendant criticized studies relied on by plaintiffs’ experts as “flawed” and “not scientifically reliable.” Defendant’s Proposed Findings of Fact and Conclusions of Law at 2. According to defendant, numerous respected scientists have conducted extensive testing and critical review of non-ionic surfactants and have concluded that the Product is safe and effective. Consolidated Pretrial Order at 9. Defendant pointed out that at least one select panel appointed by the government has concluded that the Product should carry no warning that it might cause birth defects. Id.

Finally, defendants argued that even if plaintiffs succeeded in proving a causal link between the Product and Katie Wells’ birth defects, defendant had no duty to place a warning on the Product in 1980 because of the absence of any reliable information at that time connecting spermicides and birth defects. Thus, according to defendant, the Product was not defective, defendant had not been negligent, and the failure to provide any such warning was not the result of a conscious marketing decision that might support a claim for punitive damages. Transcript at 46-47.

The Evidence at Trial

A. Mary Maihafer

Plaintiff Mary .Maihafer testified on direct examination consistently with plaintiffs’ theory of the case outlined above. Ms. Maihafer testified positively that she had used the diaphragm and spermicidal jelly according to the instructions every time she and Gary Wells had sex from late July until mid-November 1980. She further stated that she had continued to use the Product for one to two weeks after she missed her menstrual period of November 1, 1980. Transcript at 76, 80-81. Ms. Maihafer also mentioned that several months into this pregnancy she had used the prescription drug Deeadron for bronchitis and some prescribed antibiotics 6 for an ear infection. Transcript at 63-64. In addition, she testified that after Katie Wells’ birth, she interrupted her college teaching career for two years to take care of the child. Transcript at 963. On cross-examination, Ms. Maihafer admitted that she had known, at the time she obtained the diaphragm and spermicide, that diaphragms are not one hundred percent effective in preventing conception. Transcript at 122.

B. Gary Wells

Gary Wells testified that, to his knowledge, Mary Maihafer used the diaphragm and spermicide every time they had sex from the time she obtained it until mid-November 1980. Transcript at 151. Counsel for both sides questioned him about his use of drugs. He testified that he had used LSD once in 1971, amphetamines three or four times in 1979, and methaqualone in two or three doses in 1979. Further, he stated that he had smoked marijuana on infrequent occasions from 1969-72 and that he may have smoked marijuana once or twice in 1980 during the time he dated Mary Maihafer. Transcript at 147-51,155-57.

C. Dr. Bruce Buehler

Plaintiffs’ primary expert witness was Dr. Bruce Buehler, who is an associate professor of pediatrics and pathology at the University of Nebraska Medical Center, the director of the Center for Human Genetics, and the director and dean of the Meyer Children’s Rehabilitation Institute. Dr. Buehler is board-certified in pediatrics, chemical genetics, and biochemical and metabolic genetics. His research area is biochemical teratology, the study of the effects of drugs and environmental agents on developing fetuses. Transcript at 203. The list of Dr. Buehler’s credentials is long and impressive. 7

Dr. Buehler testified that the Meyer Children’s Rehabilitation Institute each year handles approximately 25,000 visits by handicapped persons from birth through age sixty. The Institute, which employs an estimated ninety professionals who work with handicapping disorders, has a national reputation that attracts patients from all over the country. Transcript at 204-06.

Dr. Buehler had examined Katie Wells in person, as opposed to merely viewing her medical records. Before testifying about his findings in the examination and his conclusions that followed, Dr. Buehler explained what a geneticist looks for in an examination to determine the cause of birth defects, and he demonstrated with Katie Wells in court certain aspects of the examination.

The doctor testified that in examining patients with birth defects, a geneticist attempts to determine at what stage of fetal development the defects or abnormalities occurred. He stated that because genetic problems “tend to do their dirty work” from the moment of conception, they result in abnormalities in the body that are symmetrical. On the other hand, Dr. Buehler explained, birth defects tend to be asymmetrical when they are caused by the environment, drugs, and a few genetic problems. Thus, in examining Katie Wells, Dr. Buehler testified that he and a colleague spent much time studying the symmetry of her body and the placement and size of her body parts. Transcript at 220-22.

Dr. Buehler explained his findings as he re-enacted portions of the examination in court with Katie Wells. What the doctor found most significant, and what the Court partially observed, was the condition of Katie’s left shoulder: the shoulder was totally smooth, the shoulder blade and scapula were half their normal size, and the size of the muscles was normal. Transcript at 227-28. Dr. Buehler testified that although most limb deficiencies show some attempt at making an arm or finger—such as a hand or piece of tissue attached to the shoulder—the complete smoothness of this shoulder was rare and suggested total disruption of the limb bud. He also found surprising the normal musculature of a shoulder with no arm. Transcript at 230.

Dr. Buehler considered and rejected the possibility that the shoulder defects were caused by “amniotic banding” that cut off the arm; if a band had been present, he stated, the clavicle and scapula behind the band would have been normal. Moreover, the hospital delivery records included no description of amniotic banding. He also rejected as inconsistent with his experience the possibility that the limb had been trapped in the womb and absorbed or destroyed by the body. He concluded that the limb defect must have been caused by a vascular disruption—an interruption in the blood supply to the developing limb. According to Dr. Buehler, the interruption prevented the development of a left arm and provided insufficient blood supply for the clavicle and scapula to reach their normal size. Transcript at 230-32, 242.

Similarly, the doctor concluded that the defects of the right hand probably were caused by a vascular disruption. Although Dr. Buehler observed that the wraps of “fiber material” around Katie Wells' fingers gave the appearance of amniotic banding, he rejected this explanation because the missing portion was in the middle—not at the end—of Katie Wells’ finger. He stated that the missing part must have once been there but disappeared, an occurrence explainable only by loss of blood supply and reabsorption. Dr. Buehler further testified that the formation of the fingers was inconsistent with amniotic banding, with which “you would expect essentially amputation.” Transcript at 232.

Although Dr. Buehler testified definitively that vascular disruption had caused the birth defects of Katie Wells’ shoulder and hand, he would not attribute her other defects to the same cause. He testified that although he could not rule out the possibility of vascular disruption, he did not have “enough data to make a cleft lip a vascular accident as I do with limb deformities.” Transcript at 233. With respect to the hypoplasia of the optic nerve, Dr. Buehler stated as follows:

It is much easier to explain eye formation and optic nerve formation on a vascular basis than it would be for me for a cleft [lip]. That is not what I ruled out or ruled in. I have not included that in my opinion because I have focused on the arms, which are the most comfortable to me.

Transcript at 234. That Dr. Buehler was careful in limiting his opinion to matters within his area of expertise greatly enhanced his credibility in the view of the Court.

Dr. Buehler identified the most likely cause of the vascular disruption in this case as the Product. He testified that diabetes, one possible source of the irritation of the vascular supply, had been ruled out in this family. Instead, Dr. Buehler stated that scientific studies supplied to him by plaintiffs and other studies he had reviewed on his own suggested that exposure to spermicides could produce a higher risk of limb defects. The doctor went on to testify that he was “more comfortable with his opinion and [did] not require the literature as strongly” because Mary Maihafer had used the spermicide not only at conception, but also through the time of development of the limb buds during the first few weeks after conception. Transcript at 243-44, 276. 8 Dr. Buehler elaborated on this conclusion, recalling that certain studies have suggested that spermicides can be absorbed and find their way to the fetal site, where they can irritate or otherwise affect fetal development. Dr. Buehler further testified that he rejected the possibility that LSD and other drugs taken by Gary Wells on occasion or Decadron and Amoxicillin taken by Mary Maihafer during this pregnancy could have caused these birth defects.

Dr. Buehler also discussed several pertinent studies and articles that he had reviewed prior to trial. The first was the 1976 Oechsli study, 9 which was prepared for the National Institutes of Health (NIH). According to Dr. Buehler, NIH generally selects excellent researchers, and epidemiologists and teratologists generally rely heavily on such data when available. Dr. Buehler described the Oechsli study as indicating a “question and possible relationship” between spermicides and birth defects. Dr. Buehler further noted that the unpublished Oechsli study was cited to in the March 1980 Harlap article, 10 which was published in a well-respected journal. In Dr. Buehler’s opinion, it appeared that the Oechsli study would have been available to the general medical community. Transcript at 247-54.

Next, Dr. Buehler addressed the 1977 Smith article. 11 Although Dr. Buehler observed that the Smith article drew no strong conclusions, he pointed out that it contained data suggesting an association between spermicides and limb deficiencies. Based on these studies, Dr. Buehler concluded that in the 1970’s the existence of a potential problem with spermicides was known. Transcript at 254-56.

Dr. Buehler also discussed the 1981 Jick article, 12 which he stated was published in the well-respected Journal of the American Medical Association. According to Dr. Buehler, this article raised a “serious question” about an association between spermicides and limb defects. He testified that after the publication of this article, he began recommending that pregnant women undergo ultrasound testing for fetal limb deficiencies twelve to eighteen weeks after conception. Transcript at 259-62.

The next study that Dr. Buehler addressed was the 1982 Buttar study of the potential embryotoxic and teratogenic effects of the non-ionic surfactant nonoxynol-9. 13 Dr. Buehler testified that this study provided a strong basis for his opinion that the spermicide was the most likely cause of Katie Wells’ arm and hand defects because it showed that the spermicide caused an increased number of fetuses to be reabsorbed in rats and in mice. In Dr. Buehler’s view, the “embryolethality” shown by this study was a “very strong suggestion” that the spermicide can reach the fetus and destroy it, a result that suggests the spermicide is teratogenic, notwithstanding the author’s stated conclusion. Transcript at 268-70.

Finally, Dr. Buehler addressed the 1982 Jick article. 14 He testified that this article showed a higher miscarriage rate in mothers who, according to Jick’s definition, used spermicides. In Dr. Buehler's opinion, this increased miscarriage rate wa,s another suggestion that spermicides are teratogenic. Transcript at 270-73.

Turning from causation to consequences, Dr. Buehler addressed the future medical expenses that would accompany Katie Wells’ birth defects. Based on his experiences with rehabilitation medicine, the doctor testified that prosthetic devices and adaptive equipment “to maximize [Katie Wells’] potential” would cost at least one to one-and-a-half million dollars. Transcript at 282-83.

Defense counsel conducted a thorough and probing cross-examination of Dr. Buehler. When asked whether the 1981 Jick study proved that spermicides caused the limb reduction defects that Jick found, Dr. Buehler answered in the negative, but explained that “there isn’t any teratogen study that has proven ‘yes’ or ‘no.’ It is an improbability risk. This raises a probability question.” Transcript at 351. Even after taking into account all the concerns raised by defense counsel, Dr. Buehler concluded, with a reasonable degree of medical certainty, that the spermicide had caused the defects in Katie Wells’ shoulder and hand. Transcript at 327.

The Court found Dr. Buehler to be the most credible of all the witnesses presented in this case. His credentials and experience in biochemical teratology were impres sive. Unlike defendant’s experts, he had personally examined Katie Wells. His uncontradicted testimony was that he formed no opinion until after this examination. His opinion at trial was the same as the opinion that he previously had offered at his deposition, which defense counsel conducted within an hour of his examination of Katie Wells. That Dr. Buehler limited his testimony to the area of his expertise— limb defects—and would not say that all Katie Wells’ defects were caused by the spermicide, made his opinion even more believable. His detailed explanation of how he had ruled out other possible causes demonstrated that his opinion was the product of a careful, methodical reasoning process, not mere speculation. His demeanor as a witness was excellent: he answered all questions fairly and openly in a balanced manner, translating technical terms and findings into common, understandable language, and he gave no hint of bias or prejudice. In short, this witness could hardly have been more credible.

D. Dr. Earl Sutherland

Another expert who testified for plaintiffs was Dr. Earl Wilbur Sutherland, III. Dr. Sutherland, who has a Ph.D. in pharmacology and an M.D., is an assistant professor of medicine in the departments of internal medicine and clinical pharmacology at the University of Colorado School of Medicine in Denver. Since 1980 he has been Medical Director of the Rocky Mountain Drug Consultation Center, which offers information about therapeutic drugs to consumers and health professionals. He is board-certified in internal medicine, and he actively practices in that field. Dr. Sutherland also worked with NIH for several years beginning in 1969. Transcript at 523-39.

Dr. Sutherland’s testimony concerned both key issues in this case: the causation of Katie Wells’ birth defects and the adequacy of defendant’s warning. Addressing causation, he testified that non-ionic surfactants work by disrupting the lining of sperm cells, thus either killing or immobilizing them. Transcript at 540-42. According to Dr. Sutherland, non-ionic surfactants are toxic to many other cells as well. He testified that, based on his research of published and unpublished materials, in his opinion spermicides have a “definite role” in causing birth defects. Transcript at 543.

Although Dr. Sutherland could not identify with certainty the “mechanism” by which spermicides can cause birth defects, he pointed out that mechanisms have not been discovered for some drugs—such as thalidomide—that are known to cause congenital malformations. Dr. Sutherland did suggest several possible mechanisms: (1) that the spermicide may have injured a sperm which nonetheless fertilized the egg, resulting in abnormal development of the fetus; (2) that the spermicide may have injured the unfertilized egg; or (3) that the spermicide may have injured the fertilized egg. Transcript at 544, 565-66. Further, Dr. Sutherland stated that non-ionic surfactants can cause vascular disruption by irritating or injuring small blood vessels. Transcript at 545-46.

Based on his personal examination of Katie Wells, his review of the relevant medical records in this case, his reading of the literature, and his knowledge and experience as a physician and pharmacologist, Dr. Sutherland concluded that the non-ionic surfactant in the Ortho-Gynol Contraceptive Jelly caused Katie Wells’ birth defects. Transcript at 565-66. He explained that non-ionic surfactants are “readily absorbed” by the mother’s body 15 and, because they are toxic to a variety of cells, they create a potential for injury not only to spermatozoa, but also to the ovum, the fertilized egg, and the fetus. Dr. Suther land also noted the existence of clinical reports suggesting an association between non-ionic surfactants and birth defects. Transcript at 565-568. Therefore, according to Dr. Sutherland, the spermicide had several opportunities to cause these birth defects in Katie Wells, and the lack of certainty about precisely which mechanism or mechanisms were involved was consistent with the uncertainty surrounding how certain known teratogens work. Transcript at 567.

Addressing the issue of failure to warn, Dr. Sutherland stated that his background had made him familiar with the pharmaceutical industry’s customary practices regarding warnings and also with the procedures followed in studies and reports made for NIH. He testified that the 1976 Oechsli study, which raised questions about a possible relationship between spermicides and birth defects, was performed under an NIH contract and that, although the study was never formally published, it would have been available to the public and the pharmaceutical industry long before Mary Maihafer purchased and used the spermicide in 1980. 16 Transcript at 553-58. According to Dr. Sutherland, the Oechsli study employed standard, widely-accepted techniques. He also stated that the pharmaceutical industry routinely relies on NIH studies. Transcript at 559-60.

Because the Oechsli study and the 1977 Smith study indicated a “serious potential” that spermicides increase the risk of fetal injury, and because both studies were available to defendant before Mary Maihafer began using the Product, Dr. Sutherland concluded that the warning on the label of the Product was inadequate. In his opinion, the Product should have carried a warning that a user should discontinue use if she suspects she is pregnant and that the Product might increase the risk of fetal malformations. Transcript at 562. This opinion, he stated, was based on the studies linking spermicides with birth defects, the known toxicity of the spermicide, and the evidence that non-ionic surfactants are absorbed by mothers using spermicides. Dr. Sutherland emphatically concluded that defendant’s failure to provide such a warning fell beneath the customary standard of care in the pharmaceutical industry. Transcript at 563.

Finding Dr. Sutherland more than qualified to address the issues of causation and failure to warn, the Court judged him to be a credible witness. Without being dogmatic, he was positive and emphatic in his conclusions that the spermicide caused Katie Wells’ birth defects and that the warning on the Product was inadequate. His manner suggested objectivity and openness. For example, he readily admitted that he could not pinpoint the mechanism by which the spermicide caused these birth defects. Furthermore, his conclusions withstood a rigorous cross-examination, and he showed no sign of bias or prejudice that might lead the Court to discount his opinion.

E. Dr. Joseph Bussey

Plaintiffs also called as a witness Dr. Joseph Gibson Bussey, a general surgeon who had been a consultant to a division of Johnson and Johnson, the parent company of defendant Ortho Pharmaceutical Corporation. Dr. Bussey testified that, in his opinion, the spermicide had caused Katie Wells’ birth defects and that the warning on the label of the Product was inadequate. Transcript at 459, 463.

Dr. Bussey’s background also included experience in evaluating disabilities: he was a founding member of the National Association of Disability Evaluating Physicians. Transcript at 430. Based on his examination of Katie Wells and his review of her medical records, Dr. Bussey testified that, in his opinion, Katie Wells is totally and permanently disabled. Transcript at 470.

With the exception of his testimony concerning the degree of Katie Wells’ disability, the Court did not place much reliance on Dr. Bussey’s testimony. Although Dr. Bussey appears to have an excellent background in surgery, his practice only occasionally involves obstetrics and gynecology, a fact underscored by defense counsel on cross-examination. Further, none of his research or writing has dealt with epidemiological studies or the causes of birth defects.

Another fact detracted from Dr. Bussey’s credibility: he testified that he first became interested in a connection between spermicides and birth defects when his wife had a spontaneous abortion after using a spermicide manufactured by defendant. Transcript at 432-37. Because of the inherent potential for bias or prejudice, the Court has given little weight to Dr. Bussey’s testimony concerning causation and failure to warn.

F. Dr. John Holbrook

Another expert witness who testified for plaintiffs was Dr. John Marshall Holbrook, the Director of Research and Associate Professor at Mercer University School of Pharmacy. Dr. Holbrook’s credentials include a B.S. in Pharmacy and a Ph.D. in Pharmacology. His background in teaching and publishing has included, among other things, the toxic effects of certain drugs on the body. Transcript at 163-72.

Dr. Holbrook described from his perspective as a pharmacologist how spermicides containing non-ionic surfactants work. He explained that non-ionic surfactants are detergents that disrupt and inactivate sperm by breaking down their cell walls. By this very mechanism, Dr. Holbrook stated, non-ionic surfactants cause irritation. Transcript at 176-78.

In Dr. Holbrook’s opinion, a “definite relationship” exists between the use of spermicides and fetal malformations. Transcript at 710-11. Dr. Holbrook based this conclusion on various articles and studies dating as far back as 1975 that suggested the existence of such a link. The earliest of these, which appeared in January 1975, 17 indicated to Dr. Holbrook that there had been little evaluation of the damage which spermicides might produce and that spermicides might cause birth defects. Transcript at 181-83.

The 1976 Oechsli study, in Dr. Holbrook’s view, was a “strong suggestion” that the use of spermicides could lead to serious birth defects. Transcript at 191. Similarly, Dr. Holbrook testified that the 1977 Smith article contained indications that spermicides might be teratogenic. Transcript at 704-05.

According to Dr. Holbrook, other articles and studies 18 published after Mary Maihaf er began using the spermicide also contributed to his conclusion of a “definite relationship” between spermicides and birth defects. Still, in his opinion, the scientific literature available before July 1980 should have prompted Ortho Pharmaceutical Corporation to warn physicians, pharmacists, and consumers of a possible increased risk of fetal malformations “at the very, very first hint of a problem with the compound.” Transcript at 718-19. Ortho’s failure to issue any such warning was contrary to the ordinary custom in the pharmaceutical industry of monitoring the available medical literature and warning of potential problems with products, according to Dr. Holbrook. Transcript at 715-19.

Dr. Holbrook further addressed whether Mary Maihafer’s consumption of alcohol during pregnancy or Gary Wells’ past drug use might change his opinion. He testified that neither of these facts would alter his conclusion concerning the relationship between spermicides and birth defects.

The Court found Dr. Holbrook to be a credible witness. His background in pharmacology gave credence to his testimony concerning the potential pharmacological effects of spermicides and the customary procedures concerning warnings in the pharmaceutical industry. His demeanor on both direct and cross-examination indicated that he was giving his honest appraisal of the issues of causation and failure to warn.

G. Dr. Dick Gourley

A most persuasive witness for plaintiffs on the issue of failure to warn was Dr. Dick Gourley. Dr. Gourley’s background and credentials are extensive: formerly a full professor and chairman of the Department of Pharmacy at the University of Nebraska, Dr. Gourley presently is a full professor and Dean of Mercer University School of Pharmacy. He has published at least thirty-seven articles and six to eight chapters in books relating to pharmacy, including a chapter in the “Handbook of Nonprescription Drugs” (the “O.T.C. Handbook”), a compendium of chapters on nonprescription products published by the American Pharmaceutical Association. Additionally, Dr. Gourley is a senior reviewer of the O.T.C. Handbook and serves on the editorial boards of two pharmaceutical journals. He has received numerous grants and contracts from private foundations, government agencies, and pharmaceutical companies. Most significantly, Dr. Gourley has served as an advisor or consultant to many major pharmaceutical firms, and in this capacity his wide range of responsibilities has included advising these drug companies what information should be included in package inserts and drug information packets. Transcript at 845-864.

Dr. Gourley stated forcefully that the warning on the label of Ortho-Gynol Contraceptive Jelly is insufficient. He testified that “as soon as the first study is done and any information that is provided ... gives the hint that there is a possibility of a drug causing birth defects,” the label should be changed to include a warning. Transcript at 870. According to Dr. Gourley, defendant should have warned that its Product carries an increased risk of birth defects soon after that possibility was suggested by the Oechsli study in 1976, and no later than the publication of the Smith study in 1977. Transcript at 870, 876-77. He explained that, according to his experience, firms in the pharmaceutical industry closely watch the workings of the scientific community—including NIH—for any information concerning their products because this information affects their business.

In Dr. Gourley’s view, the Smith study, which was published in 1977, certainly was available to defendant that same year. Further, he testified that the unpublished 1976 Oechsli study also would have been available to defendant:

The Oechsli study is a study of N.I.H., and studies such as this become public. Now, [it]’s not necessary that it has to be published in a journal for industry to get ahold of something like this. They may not have had it on April the 8th, 1976, but, if they didn’t have it within a few months of that, then somebody was asleep at the wheel.

Transcript at 871-73.

In Dr. Gourley’s opinion, an adequate warning on the Product’s label might be as simple as the following: “Do not use in case of pregnancy, and if you become pregnant while using the product, please contact or consult your physician.” Transcript at 868. Dr. Gourley emphasized the importance of a patient’s “right to know”:

[o]ur attitude towards patients has changed dramatically in the past ten years so [that] patients have a right to know information. They are demanding information; so it should have been there for the patient, without any question.

Transcript at 874. Dr. Gourley further stated that defendant also should have warned pharmacists, physicians, and family planning groups of this possibility through mailgrams or through its “detail men,” as is common in the industry when studies suggest that a product might have adverse effects. 19 Transcript at 874-76.

All in all, the Court found Dr. Gourley to be one of the most credible witnesses presented by either side. Although he had never worked with Ortho Pharmaceutical Corporation, his background and experience in the pharmaceutical community made him well-qualified to testify on customs and practices in the industry in general. He was positive in his opinion without being dogmatic. His conduct and bearing suggested a balanced, reasoned approach to answering the questions asked of him by both sides. In short, the Court found him to be a highly credible witness.

H. Dr. Dan J. Mitchell

Dr. Dan J. Mitchell was another witness presented by plaintiffs to address the issue of failure to warn. Dr. Mitchell, whose credentials in pharmacy include a B.S., Ph.D., and post-doctoral training, is Clinical Pharmacy Coordinator and Director of Drug Information at Northside Hospital in Atlanta. He has held a variety of positions that have involved the retrieval and dissemination of information about drugs. In his present capacity as Director of Drug Information, he has developed a formal drug information service to respond daily to questions from physicians and other medical staff. Transcript at 797-806.

Dr. Mitchell testified that in providing this service, he relies extensively on information provided by the manufacturer of a drug because other sources of information often are not readily available and because “the manufacturer typically will have access to virtually anything that has been reported.” Transcript at 807. He also stated that he is familiar with drug manufacturers’ customary procedures in providing information about their products. According to Dr. Mitchell, pharmaceutical firms generally furnish such information when a product is first marketed and when changes are made in labelling. Dr. Mitchell further stated that he relies on the pharmaceutical companies to provide current and accurate information about potential side effects of their products. Transcript at 808-09.

Dr. Mitchell testified that neither Ortho Pharmaceutical Corporation nor its parent, Johnson and Johnson, ever warned him of the potential teratogenic effects of the Product. After reviewing the Oechsli and Smith studies, he concluded that “[Ortho] definitely should have provided some form of warning ..., particularly to the user of the product and probably also to health professionals,” such as physicians, pharmacists, and family planning workers, of the possible relationship between spermicides and birth defects. Transcript at 809-11. In his opinion, defendant should have provided this warning in 1976 after the Oechsli study became available. Transcript at 811. The absence of such a warning led Dr. Mitchell to conclude that the package insert accompanying the Product in 1980 was insufficient. Transcript at 813-14.

On cross-examination, defense counsel questioned Dr. Mitchell at length about the significance of other studies that, unlike Oechsli and Smith, found no connection between spermicides and birth defects or that failed to replicate the findings of those two studies. Dr. Mitchell replied that these studies did not affect his opinion concerning defendant’s duty to warn. Transcript at 839. In his view, even one report suggesting that a product may cause a defect cannot be readily discounted. He stated that the existence of studies disagreeing with Oechsli and Smith does not establish conclusively that those two studies have no significance. Transcript at 822.

Dr. Mitchell further testified on cross-examination that the findings of the FDA’s Fertility and Maternal Health Drugs Advisory Committee (FMHDAC), which in 1983 concluded that the Product needs no additional warning, also had no effect on his opinions concerning defendant’s duty to warn. He stated:

Those people are readily swayed, I think, by other interests, including pharmaceutical manufacturers, other people to whom they must report and who[m] they represent. I’m not sure what the weight of one of these advisory committees should ultimately be.

Transcript at 840.

The Court found Dr. Mitchell’s testimony very creditworthy on the duty to warn issue, but assigned no weight to the portions of his testimony that spilled over into the issue of causation. Dr. Mitchell’s expertise in drug information qualified him to comment on whether defendant’s failure to warn satisfied the standards of the industry. His demeanor, particularly under the pressure of a vigorous cross-examination, showed no evasiveness, but rather a willingness to respond in a straightforward manner and to explain his answers. In short, Dr. Mitchell fared well in the Court’s assessment of his credibility.

I. Dr. John Brown

Plaintiffs presented Dr. John Brown, an economist and actuary who is an assistant professor at Georgia State University, to establish the amount of Katie Wells’ lost future earnings caused by her birth defects. The parties stipulated to Dr. Brown’s qualifications as an expert.

Dr. Brown testified that in calculating these lost earnings he used the most conservative “work life expectancy” that he knew—27.91 years—which assumed that Katie Wells would have worked from age 18 to age 45 or 46. He pointed out that if it were assumed that Katie Wells would have worked until age 65, he would have added approximately twenty more years of earnings to his estimate.

Dr. Brown produced several different calculations of the net present value of Katie Wells’ lost future earnings by using different assumptions. Under the assumption that Katie Wells would have completed only high school, at a five percent discount rate and four percent inflation rate the net present value of her lost future earnings would be $320,104; at an eleven percent discount rate and a nine percent inflation rate, that figure would be $243,402. Under the assumption that Katie Wells would have completed college, at a five percent discount rate and a four percent inflation rate, the net present value of her lost future earnings would be $415,113; at an eleven percent discount rate and a nine percent inflation rate, that figure would be $308,709. These figures, according to Dr. Brown, are based on the conclusion that Katie Wells is totally disabled. If her disability were deemed less than one hundred percent, Dr. Brown noted that these figures would be adjusted proportionately to reflect her degree of disability. Transcript at 910-27. 20

J. Dr. George S. Braun

Defendant began its case with the testimony of Dr. George S. Braun, currently Vice-President of Technical Affairs for Johnson and Johnson, Ortho’s parent corporation. After obtaining a Ph.D. in biochemistry, in 1963 Dr. Braun joined McNeil Labs, a subsidiary of Johnson and Johnson, where he . eventually became executive director of research. In 1972 he moved to defendant Ortho Pharmaceutical Corporation to become a vice-president of research. He remained at Ortho until March 1980. Transcript at 999-1002.

Dr. Braun testified that, since approximately 1950, defendant has marketed Or-tho-Gynol Contraceptive Jelly in its present form. When the Product was introduced, Dr. Braun stated, it was tested for effectiveness in preventing conception. He distinguished this spermicide from others that, in the 1960’s and early 1970’s, had contained the active ingredient phenylmercuric acetate, which an FDA panel later declared unsafe. Transcript at 1005-08.

Most of Dr. Braun’s testimony concerned his participation during the mid-1970’s on an advisory committee to the FDA, the “O.T.C. Advisory Committee,” which reviewed the safety, efficacy, and labelling of a group of over-the-counter, nonprescription products that included vaginal contraceptives. According to Dr. Braun, the Committee consisted of four or five physicians in the field of obstetrics and gynecology, one or two pharmacists, one basic scientist, one consumer representative, and Dr. Braun as industry liaison. Dr. Braun considered each member of the panel an expert in his or her field.

Dr. Braun recounted that, beginning in 1973, this panel met four or five times each year for five years and gathered all the information available concerning the safety and efficacy of various ingredients in the products that it reviewed. According to Dr. Braun, to collect information the Committee searched the available literature, advertised for information from various sources (including NIH), held two symposia, and received information supplied by Ortho. 21 Transcript at 1008-16.

In 1978 the Committee sent its final report to the FDA, and in 1980 the report was published in the Federal Register as a proposed monograph. In Dr. Braun’s words, the report classified the non-ionic surfactants tested as safe, effective, and properly labelled. Transcript at 1018-19.

Dr. Braun testified that, after reviewing the studies by Oechsli and Smith, he still concluded that in 1977 the Product did not require additional warnings relating to pregnancy. According to Dr. Braun, the “overwhelming preponderance of evidence” indicates that spermicides are not teratogenic. He suggested that the Oechsli and Smith studies were “substantially flawed”; as an example, he explained that some patients in Oechsli’s study may have used spermicides containing the unsafe ingredient phenylmercuric acetate, which is not found in the Product. In light of the “negative teratology studies and all the other data from our experience,” Dr. Braun testified, “there was just no basis for a warning.” Transcript at 1022-23.

Dr. Braun further explained that changes in labelling must be done carefully because adding a warning to the label might cause concern among women using that product. Consequently, according to Dr. Braun, these women might not use that particular contraceptive, even though other contraceptives might not be suitable for them. In his opinion, “the risks involved in pregnancy far exceed any potential risks that may be involved in this method of contraception.” Transcript at 1023-24.

On cross-examination, Dr. Braun admitted that the Harlap article, which was published in March 1980 and which referred to the unpublished 1976 Oechsli study, was available to defendant in March 1980, in time for defendant to have added a warning to the label before Mary Maihafer allegedly purchased the Product in August or September 1980. Transcript at 1041-43.

The Court did not find Dr. Braun to be a particularly credible witness in view of his interest in the outcome of the case and his lack of training as compared to many of the other witnesses.

K. Mr. Armond Welch

Defendant next presented as a witness Mr. Armond Morris Welch, a registered pharmacist who worked for the FDA from 1946 until 1980. From 1971 until 1980, Mr. Welch had been a panel administrator assigned to the O.T.C. Advisory Committee on vaginal products, the same panel on which Dr. Braun had served. According to Mr. Welch, this panel was one of many formed by the FDA to review various products. Each panel was charged with determining whether certain products were (1) “generally recognized as safe”; (2) “generally recognized as effective”; and (3) “not misbranded.” Transcript at 1056-61.

Although much of Mr. Welch’s testimony about the functioning of the panel paralleled Dr. Braun’s account, Mr. Welch did add several pertinent details. He stated that neither the industry representative, Dr. Braun, nor the consumer representative was allowed to vote, but that the voting members of the Committee solicited their views on all issues. Transcript at 1064. Mr. Welch also described the panel’s requests for information, search of the literature, two symposia, and other efforts at obtaining data on vaginal products. According to Mr. Welch, NIH was aware of the panel’s proceedings and requests for information. Transcript at 1067-77.

Quoting from the Committee’s report, Mr. Welch testified that this panel had attempted to evaluate the safety of ingredients found in over-the-counter vaginal products, but found that the available literature contained little information about most of the ingredients under review. Transcript at 1077-78. According to Mr. Welch, based on the available data and the lack of “significant adverse reports,” the panel concluded that the non-ionic surfactants used in spermicides were safe for over-the-counter use. Transcript at 1078. In Mr. Welch’s opinion, despite the panel’s concern about the scarcity of available information, the panel members felt they had sufficient information to reach this conclusion. Transcript at 1083. Moreover, Mr. Welch could recall no suggestion by the panel that spermicides containing non-ionic surfactants should carry a warning concerning teratogenicity or pregnancy. Transcript at 1085-86.

Mr. Welch added that other products containing non-ionic surfactant spermicides have since undergone the scrutiny and testing of the FDA’s “New Drug Application” procedure. At least two of these products—a vaginal sponge and a lubricated condom using non-ionic surfactants—have been approved by the FDA without any warning concerning teratogenicity or pregnancy. Transcript at 1087-89.

On cross-examination, Mr. Welch testified that at one time “there was a rumor of a report” at NIH that might have been relevant to the Committee's inquiry. He was assigned to obtain a copy of this report for the panel. According to Mr. Welch, upon inquiring about the report, he was informed that whatever the report was, it would not be available during the life of the panel. Transcript at 1103-08.

Generally, Mr. Welch was an honest but unimpressive witness. His training was not extensive, nor did his testimony as to the panel’s investigation greatly assist the Court in its findings.

L. Dr. Richard N. Watkins

Dr. Richard N. Watkins next testified for defendant. Dr. Watkins, a physician who is board-certified in emergency medicine, practices in Seattle with Group Health Cooperative of Puget Sound. He testified that he has participated in several epidemiological studies and was a co-author of the 1981 Jick study, “Vaginal Spermicides and Congenital Disorders.”

Dr. Watkins’ testimony focused on how this study had been conducted and on his criticisms of the study. He stated that he had helped obtain approval to use the records of Group Health Cooperative as a data source for the proposed study, had assisted in the collection of the data, and had reviewed between four and eight drafts of the study prior to publication. Transcript at 1118-28.

Dr. Watkins explained that the study defined persons as “presumed exposed” to spermicide if the mother had received a prescription for spermicide within eleven months before conception. Dr. Watkins then summarized the study’s findings of major congenital anomalies. Of the total population, four infants had limb reduction defects, and three of these were presumed exposed. Two infants with neoplasms were presumed exposed. Three of four infants with chromosomal anomalies were presumed exposed, as were two infants with hypospadias. 22 Dr. Watkins further observed that the study found no cleft lips, amniotic banding, or eye anomalies among those infants presumed exposed. Transcript at 1124-27.

On direct examination, Dr. Watkins testified that the first draft of the study had made him “rather ill at ease” because “there were several problems.” Transcript at 1128. The first, he stated, was the question whether mothers in the “presumed exposed” group actually had used spermicide. Second, he testified that the size of the population was too small. Third, he had reservations that “these disparate conditions were lumped together without assigning causality.” Transcript at 1128-29. Dr. Watkins testified that he voiced his objections to Dr. Jick and to members of Group Health’s medical staff; he recalled that the staff reacted negatively to the study after reviewing it. Subsequently, according to Dr. Watkins, Dr. Jick requested that Dr. Watkins have nothing more to do with the study. Transcript at 1129-34.

Dr. Watkins went on to testify that sometime after the study was published, at the request of an employee of defendant he reviewed more closely the records of some of the patients in the study. 23 He stated that, in his opinion, some mothers identified in the study as users of spermicide in fact were not using spermicide. Transcript at 1135-36, 1153. Dr. Watkins concluded that he did “not believe that any reasonable conclusion regarding the association of the use of the spermicides with congenital defects can be drawn” from this study. Transcript at 1156.

On cross-examination Dr. Watkins acknowledged that, despite his present criticism of the Jick study, he had been a co-author and had signed his name to the Jick study before it was published in the widely-read Journal of the American Medical Association. Transcript at 1161-62. Dr. Watkins admitted that prior to signing as co-author of the study, he had learned of one instance in which a nurse had discovered that one mother identified by the study as a user of spermicide actually had planned her pregnancy; nonetheless, he signed as co-author. Transcript at 1168. He further admitted that, except for that single instance, he had no other information about “presumed users” being “nonusers” until one or two months before trial, when he investigated the data underlying the study at defendant Ortho’s request. Transcript at 1169. Moreover, Dr. Watkins conceded that although he previously had indicated to certain individuals his concerns about the study’s conclusions, in the almost four years since the study was published he had never before stated these concerns publicly. Transcript at 1170. Finally, Dr. Watkins testified that he was not familiar with the studies by Oechsli, Smith, and Buttar that addressed the potentially harmful effects of spermicides on developing fetuses. Transcript at 1170-71.

Because'he had participated in the 1981 Jick study, Dr. Watkins might have been an ideal witness to comment on the validity of its conclusions. Dr. Watkins’ testimony on cross-examination, however, severely eroded his credibility. It is perplexing that a physician would risk his professional reputation by signing his name to a study about which he had serious reservations, especially when he knew the article would be published in a widely-read journal. See Transcript at 1128-35,1161. Moreover, the dispute between Doctors Jick and Watkins, when Dr. Jick requested that Dr. Watkins discontinue work on the study, creates some question about Dr. Watkins’ impartiality. Finally, that Dr. Watkins chose this courtroom as the first public forum in which to repudiate a study that he had helped conduct nearly four years earlier creates further doubt about his credibility. For these reasons, the Court found Dr. Watkins’ testimony not credible.

M. Mr. Robert M. Kirsch

Defendant also presented as a witness Mr. Robert M. Kirsch, who for the past twelve years has worked for Johnson and Johnson or one of its affiliates. For the past five years, Mr. Kirsch has been in the employ of defendant Ortho Pharmaceutical Corporation, where he presently is Manager of Regulatory Affairs, Advanced Care Products Division. Mr. Kirsch stated that he holds a bachelor’s degree in biology and that his only postgraduate training has been in business. Transcript at 1186-87.

Mr. Kirsch testified that his duties with defendant include ensuring that his division complies with federal law and managing his division’s preclinical toxicology testing. He noted that defendant has sold millions of tubes of Ortho products containing non-ionic surfactants, including but not limited to Ortho-Gynol Contraceptive Jelly. Mr. Kirsch observed that Ortho-Gynol Contraceptive Jelly was on the market before the institution of the FDA’s “New Drug Application” procedures, which require that drugs be tested in animals and humans for safety and effectiveness. Nonetheless, he stated that other Ortho products containing the same or similar non-ionic surfactants have been approved by the FDA under these procedures. Transcript at 1181-91.

Mr. Kirsch’s area of responsibility at Or-tho is animal testing, and he discussed various tests sponsored by Ortho or by other groups investigating the effects of non-ionic surfactants. According to Mr. Kirsch, these tests, which are described more fully in the footnote below, 24 attempted to mea sure irritation; toxicity, including carcinogenicity and mutagenicity (i.e., effects on genes and chromosomes); and teratogenicity. Although these tests showed that non-ionic surfactants cause mild to moderate irritation in animals, according to Mr. Kirsch they indicated no toxic or teratogenic effects. Transcript at 1194-1206.

Mr. Kirsch testified that he knew of no animal testing that has found a non-ionic surfactant to be a teratogen. When asked if he knew of any studies that indicated that non-ionic surfactants are not teratogens, he mentioned that he had seen abstracts of the Buttar study of embryotoxicity and teratogenicity, which found “no discernible skeletal malformations.” Still, Mr. Kirsch conceded that he had “very little information on the study itself,” “was not familiar with its methodology,” and that therefore it was “difficult for me to assess his results.” Transcript at 1206-09.

Mr. Kirsch criticized procedures used in the Chvapil study, which indicated that nonoxynol-9 is absorbed through the vagina. He testified that Ortho had conducted a study that could detect no absorption of nonoxynol-9 through the vagina. Transcript at 1212-14.

The testimony of Mr. Kirsch also touched on several aspects of the government’s activities in this area. Mr. Kirsch remarked that studies on the spermicide continued at Ortho even after 1980, when the O.T.C. Advisory Committee’s report deemed the Product safe and effective. He further testified that in August 1983, the FDA exempted vaginal contraceptive products from a “pregnancy warning” because they were “not intended for systemic absorption.” Transcript at 1215-17. Finally, he stated that Ortho had no control over selection of committee members of the FMHDAC, which discussed the relationship between spermicides and birth defects, but that Ortho was invited to suggest possible speakers to appear before the Committee at its December 1983 meeting. Transcript at 1219.

On cross-examination, Mr. Kirsch agreed that even though one of the Buttar studies found “no discernible skeletal malformations,” the study did conclude that the spermicide was embryolethal and fetocidal. Transcript at 1435-36. He also agreed that a significant difference between this study and the one performed by his division at Ortho was that the latter did not introduce spermicide until day six of gestation, while the former applied it at day one. Transcript at 1436.

In assessing the credibility and persuasiveness of Mr. Kirsch’s testimony, the Court was not impressed by his background. Although he testified at length about the findings of various scientific studies, his educational background in science is limited to an undergraduate degree. Moreover, his credibility suffered because at times the scope of his opinion exceeded the scope of his knowledge; for example, he readily offered his conclusion about the Buttar study of embryotoxicity and teratogenicity, despite his admitted lack of familiarity with that study. 25 See Transcript at 1206-09. Of course, that Johnson and Johnson or one of its affiliates has been Mr. Kirsch’s employer for the past twelve years added nothing to his believability. Taking into account these factors and the witness’ overall tone and demeanor at trial, the Court did not assign much weight to his testimony concerning the critical issues in this case.

N. Dr. Paul Stolley

The next expert witness to testify for defendant was Dr. Paul David Stolley, a professor of medicine and co-director of the Clinical Epidemiology Unit at the University of Pennsylvania. Dr. Stolley’s background and credentials were most impressive: he has had extensive experience in epidemiology, has served on several advisory committees to the FDA, has received numerous honors and awards, and has published 105 articles, most in the field of epidemiology. Further, he is board-certified in internal medicine and public health and is a reviewer or editor of several journals. Transcript at 1228-37.

After providing a background of epidemiological terms and principles, Dr. Stolley addressed from an epidemiologist’s viewpoint the various studies that have considered whether spermicides may cause birth defects. First, he discussed the Oechsli study, which according to Dr. Stolley “raised some small suspicion about a possibility of an association of spermicides with severe malformations.” Transcript at 1270. Dr. Stolley criticized the Oechsli study because, in his opinion, the suggested association with birth defects was not strong, the study failed to specify whether any of the spermicides in question contained phenylmercuric acetate instead of non-ionic surfactants, and the results of the study were not duplicated in certain other groups of diaphragm users. Further, Dr. Stolley noted the study’s suggestion that its finding “may have been a statistical fluke,” although he also mentioned that the study concluded that “[fjurther research is strongly indicated.” Transcript at 1269-75.

Dr. Stolley contrasted the Oechsli study with several others that have suggested no association of non-ionic surfactants with birth defects. The 1980 Harlap article and one unpublished study by Harlap, 26 which according to Dr. Stolley had a greater ability to detect a true risk than the Oechsli study, could not replicate Oechsli’s findings. A similar result in the Mills study 27 suggested to Dr. Stolley that Oechsli’s findings were a “statistical fluke.” Transcript at 1276-92.

Dr. Stolley also questioned what conclusions could be drawn from the Smith study, on which plaintiffs also relied. In Dr. Stolley’s view, the apparent association of limb defects and spermicide use noted in this study could have occurred by chance alone and was “not striking.” Additionally, the doctor noted that Smith’s data had been gathered at a time when some spermicides contained phenylmercuric acetate. Dr. Stolley stated that he concluded from Smith “that spermicides are not related to limb reduction defects.” Transcript at 1294-1301. He also testified that the completed Warburton study could not confirm the Warburton abstract’s previous suggestion that certain chromosome anomalies are related to spermicides. Transcript at 1302-04.

In Dr. Stolley’s opinion, the 1981 Jick study was the first published study to associate limb reduction defects with spermicide use. Transcript at 1318. Still, he rejected Jick’s findings. According to Dr. Stolley, Jick had so loosely defined “exposure” to spermicides that his data was “almost uninterpretable.” Transcript at 1312. Among Dr. Stolley’s other criticisms of the Jick study were that the diversity of birth defects was “biologically implausible,” that a low percentage of malformations in the control group may have artificially inflated the results, and that the size of the study was too small. If, as Dr. Watkins had suggested, two of three “presumed users” of spermicide in the Jick study were not users, according to Dr. Stolley the study would show no association between spermicides and limb reduction defects. Even without that assumption, in Dr. Stolley’s opinion, Jick’s failure to confirm exposure to spermicides made the study “so vague as to be meaningless.” Transcript at 1321-22. According to Dr. Stolley, no other studies have replicated Jick’s results, and in fact several other studies have detected no association between spermicides and birth defects. Transcript at 1304-11, 1327-43.

Based on his review of the transcript of the December 1983 meeting of the FMHDAC, Dr. Stolley testified that, in his opinion, the Committee’s discussion of spermicides and congenital abnormalities was comprehensive and thoughtful. Further, he felt that the Committee was not unduly influenced or biased by defendant Ortho Pharmaceutical Corporation. Transcript at 1345.

Finally, Dr. Stolley stated his conclusion that spermicides have been “well-studied” and have been shown “clearly” not to cause congenital anomalies, specifically limb reduction defects. Transcript at 1346. He stated that in his opinion the Product required no warning of teratogenicity in 1980. In fact, Dr. Stolley testified that such a warning would have been “irresponsible.” In his view, a proliferation of warnings causes consumers to disregard them, particularly when new data later show that no warning was necessary. Because he felt that the Product was safe, Dr. Stolley observed that a warning might do more harm than good by prompting some women to use other forms of contraception not appropriate for them or to stop using contraceptives entirely. Transcript at 1346-50.

On cross-examination, Dr. Stolley disagreed with suggestions made by plaintiffs’ experts that spermicides might cause an unpredictable variety of birth defects, such as the variety described in the Jick study. Transcript at 1369. Dr. Stolley acknowledged that his characterization of the Oechsli study as raising “some small suspicion” of an association between spermicides and malformations was inconsistent with Oechsli’s own conclusion that the study raised a “serious suspicion.” Transcript at 1373 (emphasis added).

Also on cross-examination, Dr. Stolley addressed what conclusions could properly be drawn from the Shapiro study, 28 which Dr. Stolley described as a “very good study” and on which he relied “heavily” in formulating his opinion that spermicides have been “shown clearly not to cause” birth defects. Transcript at 1346, 1406-07. Specifically, plaintiffs’ counsel questioned Dr. Stolley about the following statements made at the 1983 FMHDAC meeting by Dr. Shapiro:

There is one question that is unanswered and that we fully acknowledge, and that is that all of the cohort studies so far done, or the case control studies, for that matter, lack the power to evaluate in statistical terms that there is not an appreciable increase in the risk of specific birth defects.

I’m not for one moment claiming that this study rules out an increase in the risk of limb reduction deformities.

Transcript at 1408-10. Dr. Stolley disagreed with Shapiro that available studies could not rule out an “appreciable increase” in risk. He continued as follows:

I think that what [Shapiro] is saying is that, if there were a tiny increase in limb reduction defects, which is rare, you would need an extremely large study to absolutely rule that out and that can’t be done.

What he was trying to do is address the question of ruling out very, very tiny risks, and I think that I would agree that it’s very difficult to do that.

I think to me the data is quite conclusive in that it does not demonstrate—does not demonstrate an association of spermicides with limb reduction defects or with any other congenital anomaly.

I think that Doctor Shapiro would agree with my statement, and that is that no association between spermicides and birth defects has been shown, and I agree with him when he says a small increase cannot be ruled out. I think that’s true about a small increase in anything, but why should one even bother to do that given data that doesn’t show any substantial association as it now stands.

Transcript at 1411-13 (emphasis added).

The Court found Dr. Stolley’s credentials to be impressive and his testimony concerning the various studies to be helpful and informative. Several aspects of his testimony, however, led the Court to assign little weight to Dr. Stolley’s opinions about the ultimate issues in this case. Dr. Stolley’s responses on cross-examination and his overall demeanor and manner indicated a degree of bias. The Court also was struck by the difference between his apparent certainty on direct examination and his less-than-certain tone • on cross. Several times during direct examination, Dr. Stolley testified emphatically that a specific study or studies showed that spermicides are not related to birth defects. See, e.g., Transcript at 1301. In the portions of his testimony on cross-examination quoted above, however, Dr. Stolley equivocated. His interpretation of the studies discussed was that “no association between spermicides and birth defects has been shown,” but on cross he conceded that “a small increase [in birth defects] cannot be ruled out.” Finally, by disagreeing with Shapiro’s warning that an “appreciable increase” cannot be ruled out, Dr. Stolley in effect was expressing greater confidence in Shapiro’s findings that Shapiro himself thought was justified. Transcript at 1413. In short, because of his .apparent bias and his overstatements, the Court discounted Dr. Stolley’s conclusions.

The above passages from Dr. Stolley’s testimony are significant because they help define the Court’s role as factfinder in this case. Although these scientific studies are invaluable aids, Dr. Stolley’s testimony demonstrates that the studies alone do not show conclusively whether or not Katie Wells’ birth defects were caused by Ortho-Gynol Contraceptive Jelly. Further, the Court reiterates that plaintiffs’ ultimate burden was not to produce a flawless epidemiological study, but rather to show from all the evidence presented, to a reasonable degree of medical certainty, that the Product caused some or all of Katie Wells’ birth defects in 1980.

O. Dr. Bohdan Malyk

Defendant next presented as a witness its Director of Medical Affairs and Clinical Research, Dr. Bohdan Malyk, who sat at defense counsel’s table throughout most of the trial. Dr. Malyk is a physician who specializes in obstetrics and gynecology, who is board-certified in that field, and who has served on the faculties of several medical schools. He has held his present position with Ortho for five of the nine years that he has worked for Ortho. He testified that his responsibilities with Ortho include the following: conducting all clinical studies for Ortho’s Advanced Care Products Division, which manufactures and markets contraceptives; reviewing the available literature; reviewing the labelling of products; answering questions from health professionals and consumers; and generally setting policy for the medical research department. Transcript at 1445-50.

Dr. Malyk testified that Ortho has an “extensive capability” for keeping up with the current scientific literature. Much of his testimony concerned his comments about the various studies of the effects of spermicides. Dr. Malyk stated that he had become aware of the Oechsli study only after this lawsuit was filed. He remembered reading the Harlap article shortly after it was published in 1980 and recalled being reassured that Harlap’s findings did not replicate those mentioned in the citation to Oechsli. Based on his recent review of the Oechsli study, Dr. Malyk rejected Oechsli’s conclusions. In Dr. Malyk’s opinion, the population studied by Oechsli likely included many “high-risk” patients, making the study “essentially invalid.” He testified that he did not believe that Ortho would have acted differently even if the Oechsli study had been delivered to Ortho in 1976 or 1977. Transcript at 1451-55.

Next, Dr. Malyk stated that although he had probably read the Smith study in 1977, he did not recall reading it then. From his later review of the study, he concluded that the study was “not striking” because its authors essentially reported a negative finding. Further, Dr. Malyk suggested that because the study was Canadian, the spermicides involved may have contained active ingredients approved for use in Canada but not in the United States. According to Dr. Malyk, Ortho was correct in not changing its marketing of the Product after the Smith article was published. Transcript at 1455-57.

Dr. Malyk also commented on the Warburton abstract. He noted that the abstract was only a preliminary report of an ongoing study, and he testified that the authors’ later findings did not confirm their earlier ones. Further, he pointed out that the birth defects examined in the Warburton study were different from those suffered by Katie Wells. Transcript at 1457-61.

Dr. Malyk,next took issue with the studies suggesting vaginal absorption of non-ionic surfactants. According to Dr. Malyk, before these studies were published, his division at Ortho had begun its own study of absorption. He criticized the methodology of the Chvapil study and stated that the study’s indication that nonoxynol-9 is vaginally absorbed had not “concerned” him because he knew the methodology was not good. He also rejected the Buttar absorption study because it employed a similar methodology. 29

According to Dr. Malyk, to his knowledge the only other study addressing vaginal absorption of these ingredients was Or-tho’s own study, the preliminary report of which was published in June 1981. 30 Or-tho’s study detected no vaginal absorption of these non-ionic surfactants. Transcript at 1461-80.

Dr. Malyk also discussed various aspects of the testing and labelling of products at Ortho. He acknowledged that a warning concerning pregnancy and teratogenicity could “chill” sales of the Product, but rejected the suggestion that the lack of such a warning was financially motivated. Transcript at 1480-93.

Another matter addressed by Dr. Malyk was Mary Maihafer’s use of the spermicide. He testified that a sample tube contains three applications; a tube the size Mary Maihafer allegedly purchased contains eleven to twelve applications; and an even larger tube contains eighteen to nineteen applications. He stated that he had attempted to apply the spermicide in the same manner as Mary Maihafer had demonstrated in court and had concluded that, based on the amount she stated that she had purchased, at most she would have had eighteen applications. Transcript at 1495-99.

In assessing Dr. Malyk’s credibility, the Court first considered his background. Dr. Malyk stated that he had no formal specialized training beyond his medical degree. Moreover, he is an employee of the defendant in this case. In his testimony Dr. Malyk often was quick to offer terse, conelusory opinions that were favorable to defendant, as illustrated by his comments on both Buttar papers. 31 Based on the potential bias of this employee and based on his bearing and manner at trial, the Court concluded that Dr. Malyk was not a convincing witness.

P. Dr. Robert L. Brent

Defendant’s final and primary expert witness was Dr. Robert L. Brent. Dr. Brent is a pediatrician, embryologist, and teratologist who has a Ph.D. in embryology and radiation biology and an M.D. Dr. Brent has had very extensive experience in teaching, research, and writing. He is a full professor of pediatrics, radiology, and anatomy at Thomas Jefferson University in Philadelphia and serves as director of both the Cancer Research Institute and the Stein Research Center. He has received numerous honors and awards, and his 326 publications include many articles relating to teratology. 32

Dr. Brent testified that major birth defects occur in approximately three percent of all live births. According to Dr. Brent, the causes of sixty to sixty-five percent of these defects are unknown, and genetic causes account for another twenty to twenty-five percent of major birth defects. He stated that approximately ten percent of major defects are attributable to environmental factors, a category that includes drugs and chemicals. Transcript at 1568-81.

Dr. Brent described the first two weeks of human development as the “all or none” period. He testified that if a human embryo is injured before the 16th or 17th day after conception, according to the “all or none” principle it will either die or survive and be normal. Dr. Brent characterized this principle as not simply his opinion, but as a basic concept in embryology. 33 Tran script at 1589-91. Moreover, according to Dr. Brent’s explanation of the development of limbs and hands, the available evidence indicates that defects in limb development are not caused by exposure to a teratogen before the 24th day, when limb development begins. Further, he testified, damage to a developing hand would not occur before the 35th day. Transcript at 1594.

Based on his review of medical records and photographs of Katie Wells, 34 Dr. Brent testified that, in his opinion, none of her malformations were caused by a non-ionic surfactant. He rejected the suggestion made by some of plaintiffs’ experts that a sperm damaged by spermicide could still fertilize an egg. He also stated that while, theoretically, an egg or zygote could be killed by spermicide carried by a sperm, no limb reduction defects would result if the egg or zygote survived. Transcript at 1000-04.

Addressing the absorption studies, Dr. Brent pointed out that the Buttar study and the Ortho study conducted by Dr. Malyk showed that very little, if any, of the Product could be absorbed and reach the fetus. Transcript at 1607-09, 1618, 1624. Dr. Brent suggested that no teratogenic or embryotoxic effects can result at such low levels of concentration. Transcript at 1609, 1618-19.

The doctor characterized the other But-tar study as a poor one to measure teratogenicity. He dismissed the suggestion that Buttar’s finding that non-ionic surfactants are embryolethal and fetocidal in rats might indicate that they are teratogenic in humans. Because Buttar exposed embryos to spermicides from the earliest stages of development, according to Dr. Brent the embryolethality Buttar observed was attributable not to teratogenesis, but to the “all or none” phenomenon. Transcript at 1615. Dr. Brent was not surprised that Buttar had found no skeletal malformations because Buttar had exposed the embryos too early, in Dr. Brent’s opinion. Transcript at 1616-17.

Dr. Brent testified that if, on the 26th or 27th day, a mother stopped using an agent capable of producing limb defects, it was “unlikely” that the agent would have produced the type of limb defect suffered by Katie Wells. Transcript at 1621. In Dr. Brent’s opinion, Katie Wells’ shoulder and hand deformities and cleft lip most likely 35 were caused by the amniotic band syndrome, which the literature has never associated with non-ionic surfactants. 36 Transcript at 1628-30. Taking issue with Dr. Buehler’s conclusion, Dr. Brent did not believe the smoothness of Katie Wells’ shoulder and her underdeveloped clavicle and scapula were the result of a vascular problem. Transcript at 1635, 1638-42.

When asked how a teratologist proves or disproves teratogenicity, Dr. Brent stated that he considers whether the allegation of teratogenicity is consistent with epidemiological studies, animal studies, and basic science concepts. In Dr. Brent’s opinion, none of these three indicators suggests that non-ionic surfactants are teratogenic. Other than the Jick study, he was aware of no studies showing a statistically significant association between spermicides and birth defects. As he criticized the Jick study, he observed that it is not surprising for an occasional study to suggest an association, but that the “mass of data” must be considered. Transcript at 1643-52. Further, he commented on the limits of these scientific tests:

[T]here’s no way to prove that a substance is not teratogenic. It’s proving a negative, and, in fact, it’s true of water and vitamins and everything else that we are exposed to. All we can say is that after extensive evaluation, the risk appears no greater than if you didn’t ex pose yourself to that. That’s about as far as you can go.

Transcript at 1653-54.

Dr. Brent also discussed his involvement in this litigation, which preceded and resumed after his participation in the December 1983 FMHDAC meeting. In June 1983, according to Dr. Brent, he first met with defense counsel in this case to discuss the allegations about spermicides and birth defects. Transcript at 1654. Dr. Brent testified that he learned from defense counsel in the fall of 1983 that the FMHDAC was to discuss this issue. Because Dr. Brent was to participate as a voting member of that committee, defense counsel advised him then that he would not participate further in evaluating this case until after the FMHDAC’s hearing. On direct examination, Dr. Brent testified that he was not “retained” by defendant until March 1984. Transcript at 1655-56.

The FMHDAC, Dr. Brent explained, is a standing committee that meets two to three times yearly to discuss matters chosen by the FDA. Dr. Brent testified that at the December 1983 meeting, the Committee heard oral presentations by Doctors Jick, Harlap, Shapiro, and others and discussed the Oechsli study. According to Dr. Brent, the Committee members unanimously felt that they could not “demonstrate an increased risk or association of the alleged malformations with exposures to spermicide and that no change in the product labelling should be suggested.” Transcript at 1600.

In Dr. Brent’s opinion, an additional warning on the Product would “miseducate” the public. The result of a warning would be, in Dr. Brent’s words, a “potential major tragedy” because a warning would cause some patients to stop using the Product when the benefits to them from using it actually outweigh the risks. Transcript at 1660-63.

On cross-examination, plaintiff’s counsel elicited several items of information from Dr. Brent that placed his credibility in question. First, Dr. Brent had initially testified that he was first “retained” by Ortho in March 1984. He later revised this date as February 10, 1984. Defendant, however, described Dr. Brent’s expected testimony in interrogatory responses that were served on February 9, 1984, and that obviously must have been prepared some time prior to the date served. Transcript at 1673-74, 1702-03. Second, although Dr. Brent had discussed the allegations in this case with defense counsel in June 1983, Dr. Brent did not inform the Committee that he had previously been contacted by Ortho about this case. Transcript at 1678.

Most interesting was Dr. Brent’s past active involvement in litigation concerning contraceptives. Dr. Brent acknowledged that he had reviewed depositions and transcripts from almost 200 lawsuits concerning birth defects. Based on this review, he published an article in which he alleged that over fifty percent of plaintiffs’ expert witnesses distorted the truth, while less than ten percent of defendants’ experts had done so. Transcript at 1681-82. In another article, entitled “Lawyer-Produced Pain & Suffering,” Dr. Brent had written the following:

The case histories clearly indicate that when a family becomes orchestrated by a lawyer into the position of devoting a great deal of their energy to litigation, many of the priority family responsibilities are ignored and important critical standards are distorted. To win at all costs may be good for football teams, but it is obviously bad for a family.

Transcript at 1684-85.

When Dr. Brent attempted to explain an article in which he had criticized expert witnesses who “act as partisans rather than as scholars,” the Court asked him whether he believed that the other qualified experts in this case whose opinions were inconsistent with his were necessarily advocates for the plaintiff, or whether he acknowledged that there could be honest differences of opinions concerning what caused Katie Wells’ birth defects. Dr. Brent saw no possibility of “honest differ enees of opinion” in this case. 37 Transcript at 1685-88.

On re-direct examination, Dr. Brent testified that although he had read Dr. Buehler’s deposition, he was not aware of what Dr. Buehler had relied on in forming his conclusions, nor of any matters that Dr. Buehler did not consider. Transcript at 1700.

The Court found that although Dr. Brent’s credentials were most impressive, he was not a convincing or credible witness. His criticisms of plaintiffs’ attorneys and of expert witnesses who testify for plaintiffs in malformation lawsuits strongly suggest a distinct prejudice against plaintiffs and a corresponding bias in favor of defendants in such cases. He assisted in defense counsel’s preparation for this case in June 1983, and yet later participated in the FMHDAC’s investigation of closely related questions without disclosing his prior activities in this case. In the Court’s view, Dr. Brent’s association with Ortho before and after the December 1983 Committee meeting created serious doubts not only about Dr. Brent’s credibility ánd objectivity in this trial but also about the weight this Court should attribute to the Committee’s findings.

The exaggeration by Dr. Brent and the absolute terms in which he expressed his conclusions also detracted from his believability. Although at times he acknowledged that there is an inherent lack of certainty in determining the cause of birth defects, more often Dr. Brent’s testimony and manner suggested a degree of conviction in his own conclusions unwarranted in a discipline in which, according to other competent experts from both sides, explanations are only more or less probable. For these reasons, Dr. Brent lacked credibility as a witness.

FINDINGS OF FACT

At the close of all the evidence, the Court granted defendant’s motions to dismiss several of plaintiffs’ claims because the evidence presented by plaintiffs simply could not support them. First, the Court dismissed the claim for breach of warranty because plaintiffs had not shown the privity of contract required by Georgia law. See Watkins v. Barber-Colman Co., 625 F.2d 714, 716 (5th Cir. Unit B 1980) (applying Georgia law). Second, the Court found no evidence of negligence per se and dismissed that claim. Third, the Court dismissed the claim for negligent failure to warn that the product does not always prevent conception. The uncontradicted evidence at trial showed that the Product did carry such a warning, that Ms. Maihafer read the warning before beginning to use the Product, and that she knew that the Product is not one hundred percent effective. Fourth and fifth, the Court dismissed for lack of evidence the claims alleging fraud and “conspiracy.” Sixth, the Court found no evidence of an intentional tort by defendant and dismissed that claim also. Last, the Court concluded that plaintiffs had not shown that defendant’s failure to warn was attributable to a “conscious marketing decision” and, therefore, that the facts developed by plaintiffs at trial would not support a claim for punitive damages. Transcript at 1717-19.

Reviewing the evidence that was relevant to plaintiffs’ remaining claims, the Court made its factual findings. First, the Court found that plaintiff Mary Maihafer had properly used the Product according to the instructions every time that she and Gary Wells had sex from July 23, 1980, when she first obtained the Product, until mid-November 1980. At trial defendant presented testimony to suggest that Ms. Maihafer’s statements concerning the amount of the Product she obtained were inconsistent with her testimony about her frequency of sexual intercourse. After considering all the evidence, however, the Court found most convincing the positive testimony of Ms. Maihafer, corroborated by Gary Wells, that she had properly used the Product each time they had sex during this interval.

Next, the Court found that plaintiffs had presented insufficient evidence to establish that the Product proximately caused Katie Wells’ cleft lip and hypoplasia of the right optic nerve. Plaintiffs’ most persuasive expert witness, Dr. Buehler, could not state with a reasonable degree of medical certainty that the cleft lip and eye defect were caused by the Product, although he did not rule out that possibility. The Court found that plaintiffs’ other evidence did not prove to a reasonable degree of medical certainty that the Product caused these two defects.

With respect to the birth defects of Katie Wells’ left arm and shoulder and right hand, the Court reached a different conclusion. The Court found that plaintiffs had presented competent and credible medical and scientific evidence that showed to a reasonable degree of medical certainty that the Product proximately caused these defects. This conclusion was reached by Doctors Buehler and Sutherland—two physicians who were well-qualified to address the issue of causation, who had examined Katie Wells themselves, and who were highly credible witnesses. Dr. Holbrook’s testimony also supported this conclusion.

Defendant attempted to rebut plaintiffs’ evidence of causation through various scientific studies and reports and through its own expert witnesses. Although the studies on which defendant relied failed to detect an association between spermicides and birth defects, some of defendants’ own experts testified that these studies do not rule out all possibility that spermicides can cause birth defects. See Transcript at 1411-13 (Testimony of Dr. Stolley), 1653-54 (Testimony of Dr. Brent). Thus, although the Court assigned weight to the studies offered by defendant, in calculating this weight the Court kept in mind these studies’ limitations. Again, the Court emphasizes that its ultimate focus was the birth defects suffered by Katie Wells. Plaintiffs’ burden of proving that Katie Wells’ defects were caused by the Product did not necessarily require them to produce scientific studies showing a statistically significant association between spermicides and congenital malformations in a large population. In addition, the studies by Jick and others that indicated a possible link between spermicides and birth defects further undermine any suggestion that the studies relied on by defendant conclusively show that its Product does not cause birth defects. Consequently, the Court found the studies to be inconclusive on the ultimate issue of whether the Product caused Katie Wells’ birth defects. 38

Thus, the Court looked to the other evidence concerning causation and found that the testimony of plaintiffs’ experts conflicted with that of defendant’s experts on critical points. Plaintiffs’ experts had suggested several possible “mechanisms” of causation, and the Court found Dr. Buehler’s explanation the most plausible of these. 39 Dr. Buehler stated his opinion, to a reasonable degree of medical certainty, that the defects of Katie Wells’ left shoulder. and arm and right hand were caused by a vascular disruption. He explained that the smoothness of the left shoulder and the underdevelopment of the clavicle and scapula indicated that an interruption in the blood supply to the developing limb had caused these defects. Similarly, the absence of the middle portion of Katie Wells’ finger suggested to Dr. Buehler that the missing part had lost its blood supply and had been reabsorbed.

In contrast, Dr. Brent, testifying for defendant, stated that the most likely cause of these defects was the amniotic band syndrome, in which a band of material becomes wrapped around a body part and essentially amputates it. Dr. Buehler, however, disagreed strongly with this explanation. He maintained that if banding had occurred at Katie Wells’ left shoulder, the clavicle and scapula would not have been underdeveloped, but would have been normal-sized. Further, according to Dr. Buehler, her fingers did not show the amputation expected to result from banding. Dr. Brent never addressed these criticisms to the Court’s satisfaction. 40 In light of these criticisms and of Dr. Brent’s apparent bias, as discussed above, the Court found Dr. Buehler’s opinion about vascular disruption to be the most reasonable and believable explanation of the cause of the defects of Katie Wells’ arm and hand.

The testimony of the expert witnesses conflicted on several other key points. Dr. Buehler concluded that the spermicide was the most likely cause of the irritation of the vascular supply that resulted in these birth defects. One factor on which he relied was that Ms. Maihafer had continued to use the spermicide after conception through the time of development of the limb buds, which according to Dr. Buehler are visible by four and one-half to five weeks after conception. Dr. Brent, on the other hand, ruled out the possibility that these defects resulted from an injury to the embryo during the “all or none” period of the first seventeen days after conception. Further, Dr. Brent suggested that exposure before the twenty-fourth day would produce no limb development abnormalities.

Once again, the Court found the conclusions of plaintiffs’ expert more persuasive. One basis of this finding was the contrast between Dr. Brent’s apparent bias and the absence of any discernible bias in Dr. Buehler’s testimony. Another basis was that even assuming the validity of the “all or none” theory—which Dr. Buehler testified has been deemed “simplistic” by some authorities 41 —based on uncontradicted evidence the Court found that Ms. Maihafer had used the spermicide after the seventeen-day “all or none” period and, quite likely, even after the twenty-fourth day following conception. The timing of Ms. Maihafer’s use of the Product is consistent with Dr. Buehler’s conclusion that the vascular disruption must have occurred “much earlier” than four weeks after conception. Transcript at 275-76.

Similarly, plaintiffs’ and defendant’s experts disagreed over absorption of the Product. Plaintiffs introduced studies indicating that absorption does occur, and at least one expert witness—Dr. Sutherland— testified with a reasonable degree of medical certainty that the Product is absorbed. Transcript at 664. Testifying for defendant, Dr. Malyk attacked the validity of these studies, proclaiming the superiority of Ortho’s own studies that detected no absorption, and Dr. Brent urged that absorption could not have led to these birth defects. Again, the Court found plaintiffs’ evidence competent, credible, and free of the bias that the Court detected in the testimony of Doctors Malyk and Brent. Thus, the Court found plaintiffs’ evidence concerning absorption more believable than defendant’s.

In addition, defendant had hoped that the findings of two government review panels would negate plaintiffs’ evidence of causation. The Court found that the reports of these panels—like the various scientific studies already addressed—were entitled to some weight, but could not show conclusively whether Katie Wells’ birth defects were caused by the Product. In the Court’s view, the findings of the FMHDAC, which specifically addressed the possible teratogenicity of spermicides, are less persuasive because Dr. Brent, a participant in that inquiry, assisted defense counsel in this case before the December 1983 Committee meeting and did not disclose to the Committee his prior involvement in this lawsuit.

The preceding discussion by no means exhausts the issues that the Court considered in arriving at its finding on the issue of causation. Rather, it illustrates some important aspects of the evidence presented in this case. Plaintiffs presented competent evidence that the Product had proximately caused Katie Wells’ birth defects, and this evidence generally was credible. Defendant offered evidence that the Product was not the proximate cause of these defects, yet this evidence often lacked credibility because it reflected bias or inconsistency. Accordingly, the Court found to a reasonable degree of medical certainty that the Product had proximately caused the birth defects of Katie Wells’ left shoulder and arm and right hand.

The Court also found that at the time Ms. Maihafer obtained the Product in 1980, defendant was negligent in failing to warn that an increased risk of birth defects might accompany the use of the Product. Various articles and studies suggesting the possibility of such a risk were available to defendant prior to July 1980. These included the 1975 article “Vaginal Contraceptives—A Time for Reappraisal?”; the 1976 Oechsli study; and the 1977 Smith study. Although defendant suggested that the unpublished Oechsli study was not available, the Court found otherwise; the study was cited in the Harlap article published in March 1980, and Doctors Sutherland and Gourley testified that the study would have been available to defendant through several means. 42

Because these studies were available to defendant before July 1980, the Court found that defendant had actual or constructive knowledge that the Product might cause birth defects. This knowledge gave rise to a duty by defendant to warn consumers and certain health professionals of this possible risk. The Court agreed with Dr. Gourley’s opinion that defendant should have given such a warning no later than 1977, as soon as there was a “hint” of a possibility that the Product causes birth defects. Transcript at 870. At the time Ms. Maihafer obtained the Product in 1980, defendant had given no such warning; neither the package insert nor the label contained any warning that the Product might increase the risk of birth defects or that a user should discontinue use and consult a physician immediately if she suspects she is pregnant. Defendant’s failure to warn fell beneath the standard of ordinary and reasonable care under the circumstances. Thus, the Court found that defendant was negligent in failing to warn of this potential danger.

The Court also found that defendant’s failure to warn proximately caused Katie Wells’ arm and hand defects. Although an adequate warning about the use of the Product after pregnancy is suspected may not have enabled Ms. Maihafer to use the Product safely, it could have enabled her to decide whether to use the Product at all. Experts for defendant expressed dismay that a warning might have prompted users of the Product to switch to other types of contraceptives less “appropriate” for them. This “appropriateness,” however, should be determined by users of the Product and their physicians with access to all relevant information, not by manufacturers. Had a proper warning been given, Ms. Maihafer may well have selected an alternative, less dangerous means of birth control. Further, if defendant had warned of this increased risk, Ms. Maihafer could have consulted her physician for tests early in her pregnancy to determine whether the fetus was developing normally 43 and, if not, she would have had the option of terminating her pregnancy.

CONCLUSIONS OF LAW

Under both the negligent failure to warn and the strict products liability theories of recovery, plaintiffs bear the burden of establishing that defendant’s Product proximately caused plaintiffs’ injuries. Talley v. City Tank Corporation, 158 Ga.App. 130, 134, 279 S.E.2d 264 (1981). When medical causation is at issue, plaintiffs must prove causation to a “reasonable degree of medical certainty.” See Parrott v. Chatham County Hospital Authority, 145 Ga.App. 113, 115, 243 S.E.2d 269 (1978); Robertson v. Emory University Hospital, 611 F.2d 604, 608 n. 13 (5th Cir.1980); Watson v. United States, 346 F.2d 52, 54 (5th Cir.1965), cert. denied, 382 U.S. 976, 86 S.Ct. 544, 15 L.Ed.2d 467 (1966). Plaintiffs may not recover if the Court, acting as factfinder, determines that there was only a “bare possibility” that the Product caused these birth defects or if other theories of causation are equally plausible. See Maddox v. Houston County Hospital Authority, 158 Ga.App. 283, 284, 279 S.E.2d 732 (1981).

As discussed above, plaintiffs carried their burden of proof regarding causation. The Court found that plaintiffs had presented competent and credible medical and scientific evidence that showed to a reasonable degree of medical certainty that the Product proximately caused the birth defects of Katie Wells’ left arm and shoulder and right hand.

According to Georgia law of negligence, a manufacturer having actual or constructive knowledge that use of its product entails non-obvious, foreseeable dangers has a duty to warn users of its product of these dangers. See Rhodes v. Interstate Battery System of America, Inc., 722 F.2d 1517, 1519 (11th Cir.1984); Kicklighter v. Nails by Janee, Inc., 616 F.2d 734, 740 n. 4 (5th Cir.1980); Beam v. Omark Industries, Inc., 143 Ga.App. 142, 145, 237 S.E.2d 607 (1977). This duty, which arises “at the time of sale and delivery,” Beam, 143 Ga.App. at 145, 237 S.E.2d 607, is to exercise reasonable care in warning users of the product of such dangers. J.C. Lewis Motor Co. v. Williams, 85 Ga. App. 538, 541-42, 69 S.E.2d 816 (1952).

Plaintiffs satisfied each of these elements of this theory of negligence. The Court found that defendant had actual or constructive knowledge that the Product might cause an increased risk of birth defects because various studies suggesting this risk were available to defendant well before Ms. Maihafer first obtained the Product in 1980. Based on credible expert testimony presented by plaintiffs, the Court found that defendant’s failure to warn fell beneath the standard of ordinary care required under the circumstances. Finally, the Court found that defendant’s failure to warn proximately caused the birth defects previously identified.

The basis for strict products liability in Georgia is O.C.G.A. § 51-1-11, which provides in part that a natural person may recover against a manufacturer when he suffers injury “because the [product] when sold by the manufacturer was not mer chantable and reasonably suited for the use intended, and its condition when sold is the proximate cause of the injury sustained.” The phrase “not merchantable and reasonably suited for the use intended,” as used in this statute, means “defective.” Giordano v. Ford Motor Co., 165 Ga.App. 644, 645, 299 S.E.2d 897 (1983).

A manufacturer’s failure to warn of the dangers in using a product may constitute a defect in the product for purposes of strict liability when the manufacturer “has reason to anticipate that danger may result from a particular use.” Center Chemical Co. v. Parzini, 234 Ga. 868, 869-70, 218 S.E.2d 580 (1975) (quoting Restatement (Second) of Torts § 402A comment h (1965)).

Thus, the elements of plaintiffs’ strict liability theory are essentially the same as the elements of their theory of negligent failure to .warn. Again, plaintiffs established each of these elements. The Court found that at the time of Ms. Maihafer’s purchase of the Product in 1980, defendant knew or should have known of the potential danger that the Product might cause birth defects and that this potential danger required a warning. The absence of such a warning constituted a defect in the Product. As the Court has already discussed at length, defendant’s failure to warn proximately caused the birth defects of Katie Wells’ left arm and shoulder and right hand. In sum, the facts proven by plaintiffs at trial entitle them to recover under theories of negligent failure to warn and strict liability.

FINDINGS AND CONCLUSIONS CONCERNING DAMAGES

A. Plaintiff Katie Wells

Based on the testimony of Dr. Brown and Dr. Bussey, the Court awarded Katie Wells damages for loss of future earnings 44 in the amount of $415,000. Dr. Brown’s calculations had produced a similar figure under the assumptions that Katie Wells would have completed college, that her “work life expectancy” would have been 27.91 years, and that she is totally disabled. Given the Court’s own observations and the testimony that Katie Wells is bright and intelligent, the Court agreed that she likely would have completed college. Although the Court found that defendant is liable only for the birth defects of her left arm and shoulder and right hand, any reduction for that portion of her disability not attributable to the Product would be offset by the Court’s finding that, given her mother’s achievements and her own intelligence, her work life expectancy probably would have been considerably longer than Dr. Brown’s conservative assumption of 27.91 years.

Based on Dr. Buehler’s testimony concerning Katie Wells’ future medical expenses, including regular replacement of prosthetic devices and modification of work and living space, the Court awarded Katie Wells $1.2 million for future medical expenses associated with those birth defects proximately caused by the Product.

Based on the Court’s observations of Katie Wells during trial and the films and testimony depicting the difficulties she faces and will continue to face in performing even ordinary activities, the Court awarded Katie Wells $3 million for past and future pain and suffering caused by the birth defects attributable to the Product.

B. Plaintiff Mary Maihafer

Ms. Maihafer interrupted her college teaching career for approximately two years after Katie Wells’ birth so that she could devote her full time and attention to taking care of the child. The Court found that this interruption was proximately caused by the birth defects attributable to the Product, and, therefore, that Ms. Maihafer is entitled to compensation for her lost earnings during that period. Based on the evidence of her earnings before and after this interruption, the Court awarded Ms. Maihafer $36,000 for lost earnings. 45

Plaintiffs also sought reimbursement for certain past medical expenses incurred by Ms. Maihafer for the treatment of Katie Wells. At the conclusion of trial, the Court announced that it would award plaintiffs $3,475 in past medical expenses. The Court now modifies that award, which was based on the expenses of surgery on Katie Wells’ cleft lip and right hand. Because the surgery was performed at one time, the Court cannot determine what portion of those expenses may be attributed solely to her right hand. Plaintiffs have agreed to forego all past medical expenses except the $30 cost of an orthopedic surgeon’s examination of Katie Wells. Consequently, the award to Ms. Maihafer for past medical expenses is reduced to $30.

In addition, plaintiffs sought damages for Ms. Maihafer’s alleged physical pain and suffering and mental anguish. The Court found no evidence of physical pain and suffering by Ms. Maihafer, but did find that she suffered substantial mental distress as a result of the birth defects attributable to the Product.

The parties disagreed over whether Georgia law would allow recovery for Ms. Maihafer’s mental distress. Georgia law provides that when a plaintiff suffers a “physical injury” or “pecuniary loss,” that plaintiff’s compensatory damages may include recovery for the accompanying mental pain and suffering, even if the tortious conduct complained of is merely negligent. Westview Cemetery, Inc. v. Blanchard, 234 Ga. 540, 543, 216 S.E.2d 776 (1975).

The Court found that Ms. Maihafer is entitled to recover for her mental distress, mortification, and disappointment at the birth of her deformed child. As a result of defendant’s tortious conduct, Ms. Maihafer suffered pecuniary loss in the form of lost earnings and those of Katie Wells’ medical expenses that are attributable to the Product. See Westview Cemetery, Inc. v. Blanchard, 234 Ga. at 543, 216 S.E.2d 776. Because of this pecuniary loss, Ms. Maihafer may recover damages for the accompanying mental pain and suffering.

Alternatively, Ms. Maihafer may recover damages for her mental anguish because the “physical injury” requirement is satisfied here. According to the Court’s research, the term “physical injury” as used in the Georgia cases is much broader than a literal reading of that phrase suggests. The “physical injury” need not produce any actual physical hurt or damage to the plaintiff seeking recovery for mental anguish. 46 Some Georgia cases more accurately have referred to this requirement as the “impact rule.” As defined in Strickland v. Hodges, 134 Ga.App. 909, 910, 216 S.E.2d 706 (1975), the “impact rule” requires that defendant’s negligent conduct result in “actual bodily contact” to the plaintiff.

In this case, defendant’s negligent conduct—its failure to warn—resulted in several “bodily contacts” with Ms. Maihafer. One was Ms. Maihafer’s insertion of the diaphragm and spermicide into her body. As discussed above, Ms. Maihafer may not have used the Product at all if it had contained an adequate warning of an increased risk of birth defects. In addition,

according to all the various “mechanisms” suggested by plaintiffs’ experts in explaining how the Product might have caused Katie Wells’ birth defects—i.e., by damaging the sperm, the unfertilized or fertilized egg, or the developing fetus—Ms. Maihafer’s body was the conduit through which the damage occurred. Consequently, the Court concluded that sufficient “bodily contact” or “impact” had occurred as a result of defendant’s negligent conduct to entitle Ms. Maihafer to recover for her mental distress. 47 The Court awarded Ms. Maihafer $500,000 for her mental distress, mortification, and disappointment at the time of Katie Wells’ birth for those birth defects attributable to the Product.

DEFENDANT’S MOTION TO REOPEN

On May 13, 1985, after the Court had begun work on these findings of fact and conclusions of law, defendant moved the Court to reopen the evidence and to reconsider its announced decision on the basis of three additional articles. Plaintiffs oppose this motion.

As defendant acknowledged in its brief, decisions on motions to reopen are committed to the sound discretion of the trial court. Zenith Radio Corp. v. Hazel-tine Research, Inc., 401 U.S. 321, 331-32, 91 S.Ct. 795, 802-03, 28 L.Ed.2d 77 (1971); United States v. One 1972 44' Striker, Bonanza, 753 F.2d 867, 869 (11th Cir.1985). The Court has determined that reopening the evidence would cause undue hardship and expense for plaintiffs, who would be forced to bring back their expert witnesses to testify about the conclusions that they would draw from these articles. Further, as a case cited by defendant points out, a motion to reopen is less favorably received after the court has rendered its decision, even if formal findings of fact and conclusions of law have not been made and judgment entered. Caracci v. Brother International Sewing Machine Corp. of La., 222 F.Supp. 769, 771 (E.D.La.1963), aff’d, 341 F.2d 377 (5th Cir.1965). Every trial must end at some point. No circumstances present in this case, which was competently and thoroughly tried, warrant reopening the evidence more than three months after trial and after a decision by this Court. 48 Thus, the motion to reopen will be denied.

SUMMARY

The Court DENIES defendant’s motion to reopen the evidence and, in accordance with these findings and conclusions, DIRECTS that judgment be entered in favor of plaintiffs in the following amounts:

(1) Katie Wells:

(a) loss of future earnings $415,000

(b) future medical expenses $1,200,000

(c) past and future pain and suffering $3,000,000

(2) Mary Maihafer

(a) medical expenses of Katie Wells $30

(b) loss of earnings $36,000

(c) mental distress $500,000

The Court further DIRECTS that plaintiffs shall recover their costs of this action from defendant.

1 . Originally, this case was to have been tried before a jury. The Court specially set this case on its calendar for a specific time period, based on the parties’ initial estimates of the length of time required. The parties later revised their estimates upward and agreed to waive a jury trial so that the case could be tried within the time set aside by the Court.

2 . The only language included with these directions in this "package insert” that expressed any type of warning was the following:

PRECAUTION

If you have been advised against pregnancy for medical reasons, your birth control method should be thoroughly discussed with your physician so that both you and your physician are satisfied that the method you have selected is right for you.

ADVERSE REACTIONS

Occasional burning and/or irritation of the vagina or penis have been reported. If this occurs, discontinue use and consult your physician.

WARNING

Keep out of reach of children.

Remember, no method of birth control can absolutely guarantee against pregnancy. For maximum protection, all methods—including these—must be used according to directions.

3 . With respect to Katie Wells, plaintiffs prayed for damages for her past and future medical expenses, permanent disability, past and future pain and suffering, and "loss of earning capacity." Plaintiff Mary Maihafer sought damages for physical pain and suffering, mental anguish, “loss of earning capacity,” and loss of services of Katie Wells. The claims for “loss of earning capacity" actually were claims for loss of earnings, and the Court treated them as such. Both these plaintiffs also sought punitive damages.

4 . Plaintiffs initially presented three theories of negligence:

(1) negligent failure to warn that the Product does not always prevent conception;

(2) negligent failure to warn that if conception occurs through the spermicide’s failure, any child bora would face an increased risk of serious birth defects; and

(3) negligence per se by violation of the label-ling provisions of the Food, Drug, and Cosmetic Act.

At the conclusion of trial, the Court granted defendant's motion for involuntary dismissal of plaintiff's claims for negligence per se; negligent failure to warn that the Product does not always prevent conception; intentional tort; breach of warranty; punitive damages; and two claims added by plaintiffs at trial, fraud and “conspiracy.” Transcript at 1717-21.

5 . According to the expert testimony at trial, one other non-ionic surfactant that is essentially similar to octoxynol-9 is nonoxynoI-9.

6 . Other evidence introduced by plaintiffs identified this drug as Amoxicillin.

7 . Dr. Buehler is the recipient of numerous academic appointments; several grants, including the "Genetics and Birth Defects Service Grant”; honors and awards for teaching pediatrics and genetics and rehabilitation medicine; memberships in various professional societies; and assignments to a number of medical committees and boards. Dr. Buehler has published approximately fifty articles and abstracts, the majority in the field of biomedical teratology, including studies of upper limb anomalies. Further, Dr. Buehler has spent years treating and studying patients with handicapping disorders. Transcript at 212-19.

8 . With the aid of a slide presentation, Dr. Buehler explained that the limb buds are visible four-and-one-half to five weeks after conception. He stated that destruction of the limb bud would have to have occurred "much earlier" than four weeks after conception for a smooth shoulder such as Katie’s to result. Transcript at 275-76.

9 . Oechsli, Studies of the Consequences of Contraceptive Failure (Apr. 8, 1976) (unpublished study). The study was the "Final Report for Contract NOl-HD-5-2816” for the Contraceptive Evaluation Branch, Center for Population Research, National Institute of Child Health and Development. The author was Frank W. Oechsli, Ph.D., of the School of Public Health at the University of California, Berkeley.

10 . Harlap, Spontaneous Foetal Losses in Women Using Different Contraceptives around the Time of Conception, 9 Int’l.J. Epidemiology, Mar. 1980, at 49. In citing the Oechsli study, however, the Harlap article disagreed with it: "Previous reports [citation to Oechsli] of an excess risk associated with spermicides are not borne out by this study.” Id. at 56.

11 . Smith, An Epidemiological Study of Congenital Reduction Deformities in the Limbs, British Journal of Preventive and Social Medicine, 1977, at 39.

12 . Jick, Vaginal Spermicides and Congenital Disorders, Journal of the American Medical Association, Apr. 3, 1981, at 1329.

13 . Buttar, Assessment of the Embryotoxic and Teratogenic Potential of Nonoxynol-9 in Rats Upon Vaginal Administration, 2 The Toxicologist 39 (1982). This study concluded as follows:

"The results suggest that single vaginal application of [nonoxynol-9] is embryolethal and fetocidal but nonteratogenic in the rat at a dose approximately ten times higher than that recommended for controlling conception in women." Id. at 40.

14 . Jick, Vaginal Spermicides and Miscarriage Seen Primarily in the Emergency Room, 2 Teratogenesis, Carcinogenesis, and Mutagenesis 205 (1982).

15 . On re-direct examination Dr. Sutherland stated with a reasonable degree of medical certainty that, in his opinion, the non-ionic surfactant in the Product is absorbed by the body of the woman using the Product. The bases for his opinion included these studies: Buttar, Transvaginal Absorption of Spermicides, 13 Toxicology Letters 211 (1982); and Chvapil, Studies on Nonoxynol-9. II. Intravaginal Absorption, Distribution, Metabolism and Excretion in Rats and Rabbits, 22 Contraception 325 (1980). Transcript at 664.

16 . Dr. Sutherland testified that the Oechsli study was performed in response to a "Request for Proposal" (RFP) by the National Institute of Child Health and Development. He stated that RFPs are made known to the general public through word of mouth, through government publications, and through private services that publish RFPs. According to Dr. Sutherland, “It’s a well known thing [that] when an RFP comes out, most people who are interested in it actually already know about it.” Transcript at 551-555. His testimony suggested that defendant should have known that the Oechsli study was forthcoming even before the study was underway.

Dr. Sutherland further testified that once completed, the Oechsli study would have been available to the public under the Freedom of Information Act. Moreover, according to Dr. Sutherland, the Oechsli study was referred to in the Harlap article published in 1980, several months before Ms. Maihafer began using Ortho-Gynol Contraceptive Jelly. Transcript at 556-58.

17 . Vaginal Contraceptives—A Time for Reappraisal?, Population Reports, Jan. 1975, at H-37.

18 . For example, Dr. Holbrook noted that the 1980 Warburton abstract, Environmental Influences on Rates of Chromosome Anomalies, American Journal of Human Genetics (1980), identified spermicides as a possible factor in spontaneous abortions. This finding suggested to Dr. Holbrook that spermicides may be teratogenic. The Buttar absorption article, see supra note 15, led Dr. Holbrook to conclude that spermicides are absorbed by the user’s body and can find their way to the fetus. Transcript at 705-07. Finally, the Buttar abstract on the potential embryotoxic and teratogenic effects of nonoxynol-9, see supra note 13, suggested to Dr. Holbrook that non-ionic surfactants can damage the fetus during the early stages of gestation. Transcript at 708-09.

It is noteworthy that Dr. Holbrook found a “definite relationship” between spermicides and birth defects even though he, like Dr. Sutherland, could not identify the precise "mechanism” by which spermicides can cause birth defects. Dr. Holbrook did suggest several possi ble mechanisms that were essentially the same as those identified by Dr. Sutherland. Transcript at 710-712.

19 . The emphatic tone of Dr. Gourley’s conclusion that defendant failed to give adequate warning is evident from the following portion of his testimony:

[Y]ou can bring in a stack of studies and stack them here that says this product causes no birth defects and is not absorbed. You can bring in another stack of studies and say just the opposite here. You can line people up all day long going both directions; one is a negative study, one a positive. It (sic) doesn’t negate each other. The bottom line is, as I said earlier, number one, whether it’s this product or any other, I think the information should be placed on there: "Do not use in case of pregnancy.” I think that’s an ethical issue from my standpoint that should be on there.

Number two, you can truck experts back and forth all day long on either side of the subject, and you can go on ad infinitem. In this case you had experts going on one side of it. From my standpoint, the warning should be on there and, in my opinion, it doesn’t hurt the product, it doesn’t—and it shouldn’t be taken off the market, but the patient has the right to know, and so does the health care practitioner.

Transcript at 906-07.

20 . Plaintiffs also called as witnesses two present or former employees of defendant: James Dick Robins and Lynn Jackson. Because their testimony played no role in the Court's decision, the Court has not addressed their testimony here.

21 . In Dr. Braun’s opinion, the Committee "left no stone unturned” and was “ruthless” in its search for information. Transcript at 1019.

22 . The article summarized its findings as follows: "Among 763 liveborn infants of white women who had obtained a vaginal spermicide in the ten months before conception, the prevalence of certain major congenital anomalies was 2.2%. The prevalence of such a comparison group of 3,902 infants was 1.0%.” Jick, supra note 12, at 1329.

23 . Defendant did not make these records available to opposing counsel or to the Court. Transcript at 1138-43.

24 . According to Mr. Kirsch, beginning in 1969 Ortho conducted several tests to measure irritation caused by the Product in rats and rabbits. These studies showed mild to moderate irritation in the animals tested. Mr. Kirsch stated that although these tests are not "directly extrapolatable to humans," they are indicators of the Product’s effect on humans. Transcript at 1194-96.

Mr. Kirsch also mentioned toxicity tests using dogs and rats; these tests noted no adverse effects. Transcript at 1197-98. He discussed a study that was conducted in 1978 by a toxicologist employed by Ortho: Arbrutyn, Teratology Study of Intravaginally Administered Nonoxynol-9 Containing Contraceptive Cream in Rats, 37 Fertility and Sterility 113 (1982). According to Mr. Kirsch, this study indicated no teratological effects associated with the Product. Transcript at 1200. Next, Mr. Kirsch mentioned a rat study commissioned by Ortho that noted no carcinogenic or systemic toxic effects after two years of administration. Transcript at 1201. Additionally, Mr. Kirsch mentioned a chronic toxicity study that attempted to measure systemic safety and the 1981 Ames mutagenicity test on octoxynol-9 and nonoxynol-9, which attempted to measure the effects on chromosomes and genes. Transcript at 1202-04. Finally, Mr. Kirsch explained another Ortho study: Sodd, Teratology of lntravaginally-Administered Contraceptive Jelly Containing Nonoxynol-9 in Rats, Teratology Magazine (1984). According to Mr. Kirsch, this study noted no teratological, embryolethal, or fetocidal effects in rats whose mothers had received various doses of the spermicide in days six through fifteen of the twenty-one-day gestation period. Transcript at 1204-06.

25 . The Court recalls Dr. Holbrook’s and Dr. Buehler’s contrary interpretations of this Buttar study and points out that reasonable minds dispute Mr. Kirsch’s opinion of what conclusions should be drawn from it.

26 . Harlap, Congenital Abnormalities in the Offspring of Women Who Used Oral and Other Contraceptives around the Time of Conception (unpublished study). This study was supported by the Center for Population Research, National Institute of Child Health and Development.

27 . Mills, Are Spermicides Teratogenic?, Journal of the American Medical Association, Nov. 5, 1982, at 2148.

28 . Shapiro, Birth Defects and Vaginal Spermicides, Journal of the American Medical Association, May 7, 1982, at 2381. The Shapiro study concluded as follows:

We conclude that there is no satisfactory evidence to indicate that spermicides increase the overall risk of major birth defects. It is possible, however, that spermicides increase the risk of certain specific malformations. Our own study is not large enough to exclude such a possibility. To evaluate it, further studies are needed.

Id. at 2384.

29 . Dr. Malyk also briefly addressed the second Buttar study, which considered the embryotoxic and teratogenic effects of non-ionic surfactants in animals. For purposes of assessing Dr. Malyk’s credibility, this passage is worth reproducing here to illustrate the terse and conclusory tone that often characterized his testimony:

(On direct examination:)

Q. Then let’s go to plaintiffs’ exhibit 38, which is the other—which is the Buttar abstract. That study does reference teratogenicity, does it not?

A. Yes, I believe it does.

Q. Other than the Ortho tests, are you aware of any other animal tests which have related to teratogenicity of a spermicide?

A. I’m sorry, would you repeat that question?

Q. Other than the tests Ortho has done—

A. Unh hunh.

Q. —are you aware of any animal tests that have dealt with teratogenicity of a non-ionic surfactant other than Buttar, that particular exhibit?

A. No, I’m not.

Q. What did Ortho's test show about teratogenicity?

A. That it was non-teratogenic.

Q. What does Buttar say about it?

A. It’s non-teratogenic.

Q. Therefore, is there any animal test that you are aware of that indicates that a non-ionic surfactant is a teratogen?

A. None that I’m aware cf.

Transcript at 1472. This cursory discussion of the second Buttar study ignores the author’s findings that non-ionic surfactants may be embryolethal and fetocidal in rats, a conclusion that according to Dr. Buehler and Dr. Holbrook indicates that non-ionic surfactants may be teratogenic in humans. See supra notes 13, 18, and accompanying text.

30 . Malyk, Preliminary Results: Serum Chemistry Values Before and After the Intravaginal Administration of 5% Nonoxynol-9 Cream, 35 Fertility and Sterility 647 (1981).

31 . In addition to the testimony excerpted in note 29, an earlier passage illustrates the tone of Dr. Malyk’s testimony:

[Dr. Buttar] was subject, really, to the same shortcomings that Doctor—the same errors, unfortunately, that Dr. Chvapil made in that the material that he was using from New England Nuclear, although he says that it’s 97 percent pure in his paper, on one of the pages, I forget what page, that was really an error on his part, and, again the validity of his conclusions are really suspect.

Transcript at 1469-70. When Dr. Malyk rejects without explanation Buttar’s statement that certain material is 97 percent pure, the Court must conclude that it is the validity of Dr. Malyk’s conclusions that are "really suspect.”

32 . Dr. Brent also is a charter member, founder, and past president of the Teratology Society. He has served on the editorial boards of several journals and presently is editor-in-chief of Teratology—Study of Abnormal Development. He also has worked as a consultant with the FDA and NIH. Transcript at 1550-68.

33 . In Dr. Brent’s words, the chart on which he relied in explaining this concept “doesn’t say if they survive they will be normal, but that happens to be true.” Transcript at 1591.

34 . The Court found it significant that neither Dr. Brent nor any other of defendant's experts had ever examined Katie Wells.

35 . Other less likely possibilities suggested by Dr. Brent were that the defects were caused by a diabetic pregnancy or by some constraint in the uterus. Transcript at 1630-32.

36 . Dr. Brent stated that the causes of the amniotic band syndrome have not been found. Transcript at 1652.

37 . The following passage illustrates Dr. Brent’s viewpoint:

THE COURT: ... [I]f you have a situation where a doctor testifies on behalf of the plaintiff with the same or equal background that you have, why is it necessarily true that you are right and he’s wrong?

[DR. BRENT]: Well, obviously, I don’t think that I am wrong.

THE COURT: I understand you don’t think you are wrong. You have stated very positively that spermicides in this case did not cause this child’s defects.

[DR. BRENT]: To the best of our scientific ability to make a determination of the allegation of the teratogenicity, the data doesn’t support the allegation.

THE COURT: And, yet, we have testimony on behalf of the plaintiff to the contrary from doctors who are eminently qualified. Now, how would you explain that?

[DR. BRENT]: They are wrong.

Transcript at 1688.

38 . In finding the studies offered by defendant inconclusive on the issue of causation, the Court did not need to consider as substantive evidence the studies offered by plaintiff to suggest causation. Of course, the Oechsli study, the Smith study, the Buttar study on teratogenicity, and the Jick study all support this finding. As discussed below, the Court did consider the Oechsli and Smith studies in making its decision on the issue of failure to warn.

39 . In finding one mechanism more likely than the others suggested by plaintiffs’ experts, the Court does not discount the possible validity of those alternative explanations. Instead, the Court points out that, as more than one expert witness in this case has testified, it is not unusual that scientists sometimes cannot identify the precise mechanism by which even a known teratogen, such as thalidomide, causes birth defects.

40 . Although the Court recognized that defendant had no burden to prove the actual cause of these birth defects, Dr. Brent did propose his own theory of causation. The Court considered the criticisms of that theory in determining how much weight to attribute to his testimony.

41 . Transcript at 305.

42 . As noted previously. Dr. Gourley testified that if Ortho did not have the Oechsli study in 1976, "somebody was asleep at the wheel.” Transcript at 873.

43 . Dr. Buehler testified that after the Jick study was published, he began to recommend that mothers who used spermicides around the time of conception have ultrasound tests at twelve to fourteen weeks after conception to determine whether or not limb defects were present. Transcript at 261. If Ortho had provided such a warning, Ms. Maihafer would have had the opportunity to undergo similar testing.

44 . Although plaintiffs sought damages for Katie Wells’ “loss of earning capacity," the evidence they presented was directed to her loss of future earnings. Damages for "loss of earning capacity,” a species of general damages, were included in the Court's award to Katie Wells of damages for pain and suffering.

45 . Although plaintiffs prayed for damages for Ms. Maihafer’s "loss of earning capacity,” it was clear from the evidence presented that they actually were seeking to recover Ms. Maihafer’s lost earnings.

46 . One Georgia case relying on this proposition, Christy Brothers Circus v. Turnage, 38 Ga.App. 581, 581, 144 S.E. 680 (1928), was cited by Prosser in his discussion of how relatively minor contacts often have been held to satisfy the "physical injury” requirement. The court in Christy Brothers Circus upheld an award of damages for mental anguish when the only "physical injury" to plaintiff was that defendant’s horse had defecated into plaintiff’s lap. Id. See W. Prosser, Handbook of the Law of Torts § 54 at 331 (4th ed. 1971).

47 . The award of damages for Ms. Maihafer’s mental distress is consistent with the rationale underlying the "physical injury” requirement or "impact rule.” As Prosser has observed, "It is now more or less generally conceded that the only valid objection against recovery for mental injury is the danger of vexatious suits and fictitious claims, which has loomed very large in the opinions as an obstacle.” Prosser, supra note 46, § 54 at 328 (quoted in Hamilton v. Powell, Goldstein, Frazer & Murphy, 252 Ga. 149, 151— 52, 311 S.E.2d 818 (1984) (Clarke, J., dissenting)). No one would argue that a mother's shock and disappointment at the birth of her deformed child could be fictitious.

This award is also consistent with the statement in Davis v. Murray, 29 Ga.App. 120, 120, 113 S.E. 827 (1922), that a mother is entitled to recover damages for her mental suffering on account of her mortification and disappointment at the birth of a deformed child when defendant’s negligence has caused the deformities.

48 . Even if the Court were to reopen the evidence, the Court's review of these articles suggests that the outcome of the case would be unchanged.